source: qrda/C0Q/trunk/kids/C0Q*1.0*3.DONTUSE@ 1506

Last change on this file since 1506 was 1502, checked in by Sam Habiel, 12 years ago

Updating KIDS files; now complete; updated pre/post/tran kids routine

File size: 77.9 KB
Line 
1KIDS Distribution saved on Aug 03, 2012@10:26:28
2DFGHJKL
3**KIDS**:C0Q*1.0*3^
4
5**INSTALL NAME**
6C0Q*1.0*3
7"BLD",7936,0)
8C0Q*1.0*3^QUALITY MEASURES^0^3120803^y
9"BLD",7936,1,0)
10^^5^5^3120713^
11"BLD",7936,1,1,0)
12Created by Sam Habiel on July 13th 2012 for distribution with WorldVistA
13"BLD",7936,1,2,0)
142.0.
15"BLD",7936,1,3,0)
16
17"BLD",7936,1,4,0)
18Contains updated C0Q QUALITY MEASURES file containing the appropriate
19"BLD",7936,1,5,0)
20rule sets to use after each measure.
21"BLD",7936,4,0)
22^9.64PA^1130580001.101^1
23"BLD",7936,4,1130580001.101,0)
241130580001.101
25"BLD",7936,4,1130580001.101,222)
26y^y^f^^y^^y^o^n
27"BLD",7936,4,"B",1130580001.101,1130580001.101)
28
29"BLD",7936,6.3)
309
31"BLD",7936,"ABPKG")
32n
33"BLD",7936,"KRN",0)
34^9.67PA^779.2^20
35"BLD",7936,"KRN",.4,0)
36.4
37"BLD",7936,"KRN",.401,0)
38.401
39"BLD",7936,"KRN",.402,0)
40.402
41"BLD",7936,"KRN",.403,0)
42.403
43"BLD",7936,"KRN",.5,0)
44.5
45"BLD",7936,"KRN",.84,0)
46.84
47"BLD",7936,"KRN",3.6,0)
483.6
49"BLD",7936,"KRN",3.8,0)
503.8
51"BLD",7936,"KRN",9.2,0)
529.2
53"BLD",7936,"KRN",9.8,0)
549.8
55"BLD",7936,"KRN",19,0)
5619
57"BLD",7936,"KRN",19.1,0)
5819.1
59"BLD",7936,"KRN",101,0)
60101
61"BLD",7936,"KRN",409.61,0)
62409.61
63"BLD",7936,"KRN",771,0)
64771
65"BLD",7936,"KRN",779.2,0)
66779.2
67"BLD",7936,"KRN",870,0)
68870
69"BLD",7936,"KRN",8989.51,0)
708989.51
71"BLD",7936,"KRN",8989.52,0)
728989.52
73"BLD",7936,"KRN",8994,0)
748994
75"BLD",7936,"KRN","B",.4,.4)
76
77"BLD",7936,"KRN","B",.401,.401)
78
79"BLD",7936,"KRN","B",.402,.402)
80
81"BLD",7936,"KRN","B",.403,.403)
82
83"BLD",7936,"KRN","B",.5,.5)
84
85"BLD",7936,"KRN","B",.84,.84)
86
87"BLD",7936,"KRN","B",3.6,3.6)
88
89"BLD",7936,"KRN","B",3.8,3.8)
90
91"BLD",7936,"KRN","B",9.2,9.2)
92
93"BLD",7936,"KRN","B",9.8,9.8)
94
95"BLD",7936,"KRN","B",19,19)
96
97"BLD",7936,"KRN","B",19.1,19.1)
98
99"BLD",7936,"KRN","B",101,101)
100
101"BLD",7936,"KRN","B",409.61,409.61)
102
103"BLD",7936,"KRN","B",771,771)
104
105"BLD",7936,"KRN","B",779.2,779.2)
106
107"BLD",7936,"KRN","B",870,870)
108
109"BLD",7936,"KRN","B",8989.51,8989.51)
110
111"BLD",7936,"KRN","B",8989.52,8989.52)
112
113"BLD",7936,"KRN","B",8994,8994)
114
115"BLD",7936,"QUES",0)
116^9.62^^
117"BLD",7936,"REQB",0)
118^9.611^2^2
119"BLD",7936,"REQB",1,0)
120C0Q*1.0*2^2
121"BLD",7936,"REQB",2,0)
122QUALITY MEASURES 1.0^2
123"BLD",7936,"REQB","B","C0Q*1.0*2",1)
124
125"BLD",7936,"REQB","B","QUALITY MEASURES 1.0",2)
126
127"DATA",1130580001.101,4,0)
128PQRI MEASURE 124^^^2.16.840.1.113883.3.249.11.11
129"DATA",1130580001.101,4,1)
130Measure #124: Health Information Technology (HIT): Adoption/Use of Electronic Health Records
131"DATA",1130580001.101,4,4)
132PQRI-124
133"DATA",1130580001.101,4,5)
134Adoption/Use of Electronic Health Records (EHR)
135"DATA",1130580001.101,4,6,0)
136^^3^3^3101013^
137"DATA",1130580001.101,4,6,1,0)
138Documents whether provider has adopted and is using health inf
139"DATA",1130580001.101,4,6,2,0)
140ormation technology. To qualify, the provider must havea adopted and be
141"DATA",1130580001.101,4,6,3,0)
142using a certified/qualified electronic health record (EHR)
143"DATA",1130580001.101,4,7)
144^^^^
145"DATA",1130580001.101,6,0)
146PQRI MEASURE 47^^^2.16.840.1.113883.3.249.11.52
147"DATA",1130580001.101,6,1)
148Measure #47: Advance Care Plan
149"DATA",1130580001.101,6,4)
150PQRI-47
151"DATA",1130580001.101,6,5)
152Advance Care Plan
153"DATA",1130580001.101,6,6,0)
154^1130580001.111^5^5^3101014^^^
155"DATA",1130580001.101,6,6,1,0)
156Percentage of patients age 65 and older who have an advanced care plan or
157"DATA",1130580001.101,6,6,2,0)
158surrogate decision maker documented in the medical record or documented
159"DATA",1130580001.101,6,6,3,0)
160in the medical record that an advance care plan was discussed but the
161"DATA",1130580001.101,6,6,4,0)
162patient did not wish or was not able to name a surrogate decision maker
163"DATA",1130580001.101,6,6,5,0)
164or provide an advance care plan.
165"DATA",1130580001.101,6,7)
166^^^^
167"DATA",1130580001.101,7,0)
168PQRI MEASURE 48^^^2.16.840.1.113883.3.249.11.53
169"DATA",1130580001.101,7,1)
170Measure #48: Urinary Incontinence: Assessment of Presence or Absence of Urinary Incontinence in Women Aged 65 Years and Older
171"DATA",1130580001.101,7,4)
172PQRI-48
173"DATA",1130580001.101,7,5)
174Assessment of Presence or Absence of Urinary Incontinence in Women Aged 65 Years and Older
175"DATA",1130580001.101,7,6,0)
176^^3^3^3101013^
177"DATA",1130580001.101,7,6,1,0)
178Percentage of patients equal to or older than 65 years of age at the
179"DATA",1130580001.101,7,6,2,0)
180beginning of the measurement perion who were assesed for the presence or
181"DATA",1130580001.101,7,6,3,0)
182absence of urinary incontinence within 12 months
183"DATA",1130580001.101,7,7)
184^^^^
185"DATA",1130580001.101,12,0)
186MU EP NQF 0043^^^2.16.840.1.113883.3.249.11.8
187"DATA",1130580001.101,12,1)
188Measure #111: Preventive Care and Screening: Pneumonia Vaccination for Patients 65 Years and Older
189"DATA",1130580001.101,12,4)
190PQRI-111
191"DATA",1130580001.101,12,5)
192Pneumonia Vaccination for Patients 65 Years and Older
193"DATA",1130580001.101,12,6,0)
194^1130580001.111^2^2^3120730^^
195"DATA",1130580001.101,12,6,1,0)
196Percentage of patients afed 65 years and older who have ever r
197"DATA",1130580001.101,12,6,2,0)
198eceived a pneumoccal vaccine
199"DATA",1130580001.101,14,0)
200PQRI MEASURE 39^^^2.16.840.1.113883.3.249.11.51
201"DATA",1130580001.101,14,1)
202Measure #39: Screening or Therapy for Osteoporosis for Women Aged 65 Years and Older
203"DATA",1130580001.101,14,4)
204PQRI-39
205"DATA",1130580001.101,14,5)
206Screening or Therapy for Osteoporosis for Women Aged 65 Years and Older
207"DATA",1130580001.101,14,6,0)
208^^3^3^3101013^
209"DATA",1130580001.101,14,6,1,0)
210Percentage of patients who had a DXA measurement ordered or pe
211"DATA",1130580001.101,14,6,2,0)
212rformed at least once since age 60 or pharmacologic therapy prescribed
213"DATA",1130580001.101,14,6,3,0)
214within 12 months before the end of the measurement period
215"DATA",1130580001.101,14,7)
216^^^^
217"DATA",1130580001.101,16,0)
218PQRI MEASURE 173^^^2.16.840.1.113883.3.249.11.55
219"DATA",1130580001.101,16,1)
220Measure #173: Preventive Care and Screening: Unhealthy Alcohol Use - Screening
221"DATA",1130580001.101,16,4)
222PQRI-173
223"DATA",1130580001.101,16,5)
224Preventive Care and Screening: Unhealthy Alcohol Use - Screening
225"DATA",1130580001.101,16,6,0)
226^^2^2^3101013^
227"DATA",1130580001.101,16,6,1,0)
228Percentage of patients aged 18 years and older who were screen
229"DATA",1130580001.101,16,6,2,0)
230ed for unhealthy alcohol use using a systematic method within 24 months
231"DATA",1130580001.101,16,7)
232^^^^
233"DATA",1130580001.101,23,0)
234MU HOS NQF 0495^^
235"DATA",1130580001.101,23,1)
236ED THROUGHPUT ARRIVAL TO DEPARTURE
237"DATA",1130580001.101,23,5)
238ED THROUGHPUT ARRIVAL TO DEPARTURE
239"DATA",1130580001.101,23,6,0)
240^1130580001.111^3^3^3110430^^^^
241"DATA",1130580001.101,23,6,1,0)
242Median time from emergency department arrival to time of departure from
243"DATA",1130580001.101,23,6,2,0)
244the emergency room for patients admitted to the facility from the
245"DATA",1130580001.101,23,6,3,0)
246emergency department
247"DATA",1130580001.101,23,7)
248NQF0495^^^^^^88^165
249"DATA",1130580001.101,24,0)
250MU HOS NQF 0497^^
251"DATA",1130580001.101,24,1)
252ED THROUGHPUT ADMITTING DECISION TO DEPARTURE
253"DATA",1130580001.101,24,5)
254ED THROUGHPUT ADMITTING DECISION TO DEPARTURE
255"DATA",1130580001.101,24,6,0)
256^^3^3^3110430^
257"DATA",1130580001.101,24,6,1,0)
258Median time from admit decision time to time of departure from the
259"DATA",1130580001.101,24,6,2,0)
260emergency department of emergency department patients admitted to
261"DATA",1130580001.101,24,6,3,0)
262inpatient status
263"DATA",1130580001.101,24,7)
264NQF0497^^^^^^90^168
265"DATA",1130580001.101,25,0)
266MU HOS NQF 0435^^
267"DATA",1130580001.101,25,1)
268Ischemic stroke.Discharge on anti-thrombotics
269"DATA",1130580001.101,25,5)
270 Ischemic stroke.Discharge on anti-thrombotic
271"DATA",1130580001.101,25,6,0)
272^^2^2^3110430^
273"DATA",1130580001.101,25,6,1,0)
274Ischemic stroke patients prescribed antithrombotic therapy at hospital
275"DATA",1130580001.101,25,6,2,0)
276discharge
277"DATA",1130580001.101,25,7)
278NQF0435^^^^^^114^115
279"DATA",1130580001.101,26,0)
280MU HOS NQF 0436^^
281"DATA",1130580001.101,26,1)
282 Ischemic stroke.Anticoagulation for A-fib/flutter
283"DATA",1130580001.101,26,5)
284Ischemic stroke.Anticoagulation for A-fib/flutter
285"DATA",1130580001.101,26,6,0)
286^1130580001.111^2^2^3110430^^^
287"DATA",1130580001.101,26,6,1,0)
288 Ischemic stroke patients with atrial fibrillation/flutter who are
289"DATA",1130580001.101,26,6,2,0)
290prescribed anticoagulation therapy at hospital discharge
291"DATA",1130580001.101,26,7)
292NQF0436^^^^^^116^117
293"DATA",1130580001.101,27,0)
294MU HOS NQF 0437^^
295"DATA",1130580001.101,27,1)
296 Ischemic stroke.Thrombolytic therapy for patients arriving within 2 hours of symptom onset
297"DATA",1130580001.101,27,5)
298Ischemic stroke.Thrombolytic therapy for patients arriving within 2 hours of symptom onset
299"DATA",1130580001.101,27,6,0)
300^^3^3^3110430^
301"DATA",1130580001.101,27,6,1,0)
302Acute ischemic stroke patients who arrive at this hospital within 2
303"DATA",1130580001.101,27,6,2,0)
304hours of time last known well and for whom IV t-PA was initiated at this
305"DATA",1130580001.101,27,6,3,0)
306hospital within 3 hours of time last known well.
307"DATA",1130580001.101,27,7)
308NQF0437^^^^^^119^118
309"DATA",1130580001.101,28,0)
310MU HOS NQF 0438^^
311"DATA",1130580001.101,28,1)
312Ischemic or hemorrhagic stroke.Antithrombotic therapy by day 2
313"DATA",1130580001.101,28,5)
314Ischemic or hemorrhagic stroke.Antithrombotic therapy by day 2
315"DATA",1130580001.101,28,6,0)
316^^2^2^3110430^
317"DATA",1130580001.101,28,6,1,0)
318Ischemic stroke patients administered antithrombotic therapy by the
319"DATA",1130580001.101,28,6,2,0)
320end of hospital day 2.
321"DATA",1130580001.101,28,7)
322NQF0438^^^^^^120^121
323"DATA",1130580001.101,29,0)
324MU HOS NQF 0439^^
325"DATA",1130580001.101,29,1)
326Ischemic stroke.Discharge on statins
327"DATA",1130580001.101,29,5)
328Ischemic stroke.Discharge on statins
329"DATA",1130580001.101,29,6,0)
330^^3^3^3110430^
331"DATA",1130580001.101,29,6,1,0)
332Ischemic stroke patients with LDL > 100 mg/dL, or LDL not measured, or,
333"DATA",1130580001.101,29,6,2,0)
334who were on a lipid-lowering medication prior to hospital arrival are
335"DATA",1130580001.101,29,6,3,0)
336prescribed statin medication at hospital discharge
337"DATA",1130580001.101,29,7)
338NQF0439^^^^^^122^123
339"DATA",1130580001.101,30,0)
340MU HOS NQF 0440^^
341"DATA",1130580001.101,30,1)
342Ischemic or hemorrhagic stroke.Stroke education
343"DATA",1130580001.101,30,5)
344Ischemic or hemorrhagic stroke.Stroke education
345"DATA",1130580001.101,30,6,0)
346^^5^5^3110430^
347"DATA",1130580001.101,30,6,1,0)
348Ischemic or hemorrhagic stroke patients or their caregivers who were
349"DATA",1130580001.101,30,6,2,0)
350given educational materials during the hospital stay addressing all of the
351"DATA",1130580001.101,30,6,3,0)
352following: activation of emergency medical system, need for follow-up
353"DATA",1130580001.101,30,6,4,0)
354after discharge, medications prescribed at discharge, risk factors for
355"DATA",1130580001.101,30,6,5,0)
356stroke, and warning signs and symptoms of stroke.
357"DATA",1130580001.101,30,7)
358NQF0440^^^^^^124^125
359"DATA",1130580001.101,31,0)
360MU HOS NQF 0441^^
361"DATA",1130580001.101,31,1)
362Ischemic or hemorrhagic stroke.Rehabilitation assessment
363"DATA",1130580001.101,31,5)
364Ischemic or hemorrhagic stroke.Rehabilitation assessment
365"DATA",1130580001.101,31,6,0)
366^^2^2^3110430^
367"DATA",1130580001.101,31,6,1,0)
368Ischemic or hemorrhagic stroke patients who were assessed for
369"DATA",1130580001.101,31,6,2,0)
370rehabilitation services.
371"DATA",1130580001.101,31,7)
372NQF0441^^^^^^126^127
373"DATA",1130580001.101,32,0)
374MU HOS NQF 0371^^
375"DATA",1130580001.101,32,1)
376VTE prophylaxis within 24 hours of arrival
377"DATA",1130580001.101,32,5)
378VTE prophylaxis within 24 hours of arrival
379"DATA",1130580001.101,32,6,0)
380^^4^4^3110430^
381"DATA",1130580001.101,32,6,1,0)
382This measure assesses the number of patients who received VTE prophylaxis
383"DATA",1130580001.101,32,6,2,0)
384or have documentation why no VTE prophylaxis was given the day of or the
385"DATA",1130580001.101,32,6,3,0)
386day after hospital admission or surgery end date for surgeries that start
387"DATA",1130580001.101,32,6,4,0)
388the day of or the day after hospital admission.
389"DATA",1130580001.101,32,7)
390NQF0371^^^^^^69^67
391"DATA",1130580001.101,33,0)
392MU HOS NQF 0372^^
393"DATA",1130580001.101,33,1)
394ICU VTE prophylaxis
395"DATA",1130580001.101,33,5)
396ICU VTE prophylaxis
397"DATA",1130580001.101,33,6,0)
398^^5^5^3110430^
399"DATA",1130580001.101,33,6,1,0)
400This measure assesses the number of patients who received VTE prophylaxis
401"DATA",1130580001.101,33,6,2,0)
402or have documentation why no VTE prophylaxis was given the day of or the
403"DATA",1130580001.101,33,6,3,0)
404day after the initial admission (or transfer) to the Intensive Care Unit
405"DATA",1130580001.101,33,6,4,0)
406(ICU) or surgery end date for surgeries that start the day of or the day
407"DATA",1130580001.101,33,6,5,0)
408after ICU admission (or transfer).
409"DATA",1130580001.101,33,7)
410NQF0372^^^^^^128^71
411"DATA",1130580001.101,34,0)
412MU HOS NQF 0373^^
413"DATA",1130580001.101,34,1)
414Anticoagulation overlap therapy
415"DATA",1130580001.101,34,5)
416Anticoagulation overlap therapy
417"DATA",1130580001.101,34,6,0)
418^^8^8^3110430^
419"DATA",1130580001.101,34,6,1,0)
420This measure assesses the number of patients diagnosed with confirmed VTE
421"DATA",1130580001.101,34,6,2,0)
422who received an overlap of parenteral (intravenous [IV] or subcutaneous
423"DATA",1130580001.101,34,6,3,0)
424[subcu]) anticoagulation and warfarin therapy. For patients who received
425"DATA",1130580001.101,34,6,4,0)
426less than five days of overlap therapy, they must be discharged on both
427"DATA",1130580001.101,34,6,5,0)
428medications. Overlap therapy must be administered for at least five days
429"DATA",1130580001.101,34,6,6,0)
430with an international normalized ratio (INR) . 2 prior to discontinuation
431"DATA",1130580001.101,34,6,7,0)
432of the parenteral anticoagulation therapy or the patient must be
433"DATA",1130580001.101,34,6,8,0)
434discharged on both medications.
435"DATA",1130580001.101,34,7)
436NQF0373^^^^^^129^144
437"DATA",1130580001.101,35,0)
438MU HOS NQF 0374^^
439"DATA",1130580001.101,35,1)
440Platelet monitoring on unfractionated heparin
441"DATA",1130580001.101,35,5)
442Platelet monitoring on unfractionated heparin
443"DATA",1130580001.101,35,6,0)
444^^10^10^3110430^
445"DATA",1130580001.101,35,6,1,0)
446This measure assesses the number of patients diagnosed with confirmed VTE
447"DATA",1130580001.101,35,6,2,0)
448who received intravenous (IV) UFH therapy dosages AND had their platelet
449"DATA",1130580001.101,35,6,3,0)
450counts monitored using defined parameters such as a nomogram or
451"DATA",1130580001.101,35,6,4,0)
452protocol This measure assesses the number of patients diagnosed with
453"DATA",1130580001.101,35,6,5,0)
454confirmed VTE who received intravenous (IV) UFH therapy dosages AND had
455"DATA",1130580001.101,35,6,6,0)
456their platelet counts monitored using defined parameters such as a
457"DATA",1130580001.101,35,6,7,0)
458nomogram or protocol This measure assesses the number of patients
459"DATA",1130580001.101,35,6,8,0)
460diagnosed with confirmed VTE who received intravenous (IV) UFH therapy
461"DATA",1130580001.101,35,6,9,0)
462dosages AND had their platelet counts monitored using defined parameters
463"DATA",1130580001.101,35,6,10,0)
464such as a nomogram or protocol
465"DATA",1130580001.101,35,7)
466NQF0374^^^^^^145^146
467"DATA",1130580001.101,36,0)
468MU HOS NQF 0375^^
469"DATA",1130580001.101,36,1)
470VTE discharge instructions
471"DATA",1130580001.101,36,5)
472VTE discharge instructions
473"DATA",1130580001.101,36,6,0)
474^^11^11^3110430^
475"DATA",1130580001.101,36,6,1,0)
476This measure assesses the number of patients diagnosed with confirmed VTE
477"DATA",1130580001.101,36,6,2,0)
478that are discharged to home, to home with home health, home hospice or
479"DATA",1130580001.101,36,6,3,0)
480discharged/transferred to court/law enforcement on warfarin with written
481"DATA",1130580001.101,36,6,4,0)
482discharge instructions that address all four criteria: compliance issues,
483"DATA",1130580001.101,36,6,5,0)
484dietary advice, follow-up This measure assesses the number of patients
485"DATA",1130580001.101,36,6,6,0)
486diagnosed with confirmed VTE that are discharged to home, to home with
487"DATA",1130580001.101,36,6,7,0)
488home health, home hospice or discharged/transferred to court/law
489"DATA",1130580001.101,36,6,8,0)
490enforcement on warfarin with written discharge instructions that address
491"DATA",1130580001.101,36,6,9,0)
492all four criteria: compliance issues, dietary advice, follow-up
493"DATA",1130580001.101,36,6,10,0)
494monitoring, and information about the potential for adverse drug
495"DATA",1130580001.101,36,6,11,0)
496reactions/interactions.
497"DATA",1130580001.101,36,7)
498NQF0375^^^^^^147^156
499"DATA",1130580001.101,37,0)
500MU HOS NQF 0376^^
501"DATA",1130580001.101,37,1)
502Incidence of potentially preventable VTE
503"DATA",1130580001.101,37,5)
504Incidence of potentially preventable VTE
505"DATA",1130580001.101,37,6,0)
506^^4^4^3110430^
507"DATA",1130580001.101,37,6,1,0)
508This measure assesses the number of patients diagnosed with confirmed VTE
509"DATA",1130580001.101,37,6,2,0)
510during hospitalization (not present on arrival) who did not receive VTE
511"DATA",1130580001.101,37,6,3,0)
512prophylaxis between hospital admission and the day before the VTE
513"DATA",1130580001.101,37,6,4,0)
514diagnostic testing order date.
515"DATA",1130580001.101,37,7)
516NQF0376^^^^^^158^162
517"DATA",1130580001.101,39,0)
518MU EP NQF 0421^^^2.16.840.1.113883.3.249.11.54
519"DATA",1130580001.101,39,1)
520NQF0421 Adult Weight Screening and Follow-Up
521"DATA",1130580001.101,39,4)
522PQRI-128
523"DATA",1130580001.101,39,5)
524NQF0421 Adult Weight Screening and Follow-Up
525"DATA",1130580001.101,39,6,0)
526^1130580001.111^6^6^3110628^^^^
527"DATA",1130580001.101,39,6,1,0)
528Percentage of patients aged 18
529"DATA",1130580001.101,39,6,2,0)
530years and older with a calculated BMI in the past
531"DATA",1130580001.101,39,6,3,0)
532six months or during the current visit documented in
533"DATA",1130580001.101,39,6,4,0)
534the medical record AND if the most recent BMI is
535"DATA",1130580001.101,39,6,5,0)
536outside parameters, a follow-up plan is
537"DATA",1130580001.101,39,6,6,0)
538documented.
539"DATA",1130580001.101,39,7)
540NQF0421^^^^^^321^320^10
541"DATA",1130580001.101,40,0)
542MU EP NQF 0013^^^2.16.840.1.113883.3.249.11.56
543"DATA",1130580001.101,40,1)
544NQF0013 Hypertension: Blood Pressure Measurement
545"DATA",1130580001.101,40,4)
546PQRI-13
547"DATA",1130580001.101,40,5)
548NQF0013 Hypertension: Blood Pressure Measurement
549"DATA",1130580001.101,40,6,0)
550^1130580001.111^4^4^3110628^^
551"DATA",1130580001.101,40,6,1,0)
552Percentage of patient visits for patients
553"DATA",1130580001.101,40,6,2,0)
554aged 18 years and older with a diagnosis of hypertension
555"DATA",1130580001.101,40,6,3,0)
556who have been seen for at least 2 office visits, with blood
557"DATA",1130580001.101,40,6,4,0)
558pressure (BP) recorded
559"DATA",1130580001.101,40,7)
560NQF0013^^^^^^142^167
561"DATA",1130580001.101,41,0)
562MU EP NQF 0028A^^^2.16.840.1.113883.3.249.11.59
563"DATA",1130580001.101,41,1)
564NQF0028A Preventive Care and Screening Measure Pair: a. Tobacco Use Assessment,b. Tobacco Cessation Intervention
565"DATA",1130580001.101,41,4)
566PQRI-28
567"DATA",1130580001.101,41,5)
568NQF0028A Tobacco Use Assessment
569"DATA",1130580001.101,41,6,0)
570^1130580001.111^7^7^3110625^^^
571"DATA",1130580001.101,41,6,1,0)
572 Percentage of patients aged 18 years and
573"DATA",1130580001.101,41,6,2,0)
574older who have been seen for at least 2 office visits who
575"DATA",1130580001.101,41,6,3,0)
576were queried about tobacco use one or more times within
577"DATA",1130580001.101,41,6,4,0)
57824 months b. Percentage of patients aged 18 years and
579"DATA",1130580001.101,41,6,5,0)
580older identified as tobacco users within the past 24
581"DATA",1130580001.101,41,6,6,0)
582months and have been seen for at least 2 office visits,
583"DATA",1130580001.101,41,6,7,0)
584who received cessation intervention.
585"DATA",1130580001.101,41,7)
586NQF0028A^^^^^^157^160
587"DATA",1130580001.101,42,0)
588MU EP NQF 0041^^^2.16.840.1.113883.3.249.11.7
589"DATA",1130580001.101,42,1)
590Preventive Care and Screening: Influenza Immunization for Patients >= 50 Years Old
591"DATA",1130580001.101,42,4)
592PQRI-110
593"DATA",1130580001.101,42,5)
594NQF0041 Influenza Immunization 50 years and older
595"DATA",1130580001.101,42,6,0)
596^^4^4^3110430^
597"DATA",1130580001.101,42,6,1,0)
598Percentage of patients aged 50 years
599"DATA",1130580001.101,42,6,2,0)
600and older who received an influenza immunization
601"DATA",1130580001.101,42,6,3,0)
602during the flu season (September through
603"DATA",1130580001.101,42,6,4,0)
604February).
605"DATA",1130580001.101,42,7)
606NQF0041^^^^^^242^243
607"DATA",1130580001.101,43,0)
608MU EP NQF 0024^^
609"DATA",1130580001.101,43,1)
610NQF0024 Weight Assessment and Counseling for Children and Adolescents
611"DATA",1130580001.101,43,5)
612NQF0024 Weight Assessment and Counseling for Children and Adolescents
613"DATA",1130580001.101,43,6,0)
614^^6^6^3110430^
615"DATA",1130580001.101,43,6,1,0)
616Percentage of patients 2 -17 years of age
617"DATA",1130580001.101,43,6,2,0)
618who had an outpatient visit with a Primary Care Physician
619"DATA",1130580001.101,43,6,3,0)
620(PCP) or OB/GYN and who had evidence of BMI
621"DATA",1130580001.101,43,6,4,0)
622percentile documentation, counseling for nutrition and
623"DATA",1130580001.101,43,6,5,0)
624counseling for physical activity during the measurement
625"DATA",1130580001.101,43,6,6,0)
626year.
627"DATA",1130580001.101,43,7)
628NQF0024^^^^^^151^149
629"DATA",1130580001.101,44,0)
630MU EP NQF 0038^^^2.16.840.1.113883.3.249.11.60
631"DATA",1130580001.101,44,1)
632Childhood Immunization Status
633"DATA",1130580001.101,44,4)
634PQRI-38
635"DATA",1130580001.101,44,5)
636Childhood Immunization Status
637"DATA",1130580001.101,44,6,0)
638^^14^14^3110430^
639"DATA",1130580001.101,44,6,1,0)
640Percentage of children 2 years of age who
641"DATA",1130580001.101,44,6,2,0)
642had four diphtheria, tetanus and acellular pertussis
643"DATA",1130580001.101,44,6,3,0)
644(DTaP); three polio(IPV), one measles, ,mumps and
645"DATA",1130580001.101,44,6,4,0)
646rubella (MMR); two H influenza type B (HiB); three
647"DATA",1130580001.101,44,6,5,0)
648Percentage of children 2 years of age who
649"DATA",1130580001.101,44,6,6,0)
650had four diphtheria, tetanus and acellular pertussis
651"DATA",1130580001.101,44,6,7,0)
652(DTaP); three polio(IPV), one measles, ,mumps and
653"DATA",1130580001.101,44,6,8,0)
654rubella (MMR); two H influenza type B (HiB); three
655"DATA",1130580001.101,44,6,9,0)
656hepatitis B (Hep B); one chicken pox (VZV); four
657"DATA",1130580001.101,44,6,10,0)
658pneumococcal conjugate (PCV); two hepatitis A (Hep A);
659"DATA",1130580001.101,44,6,11,0)
660two or three rotavirus (RV); and two influenza (flu)
661"DATA",1130580001.101,44,6,12,0)
662vaccines by their second birthday. The measure
663"DATA",1130580001.101,44,6,13,0)
664calculates a rate for each vaccine and nine separate
665"DATA",1130580001.101,44,6,14,0)
666combination rates.
667"DATA",1130580001.101,44,7)
668NQF0038^^^^
669"DATA",1130580001.101,45,0)
670MU EP NQF 0059^^^2.16.840.1.113883.3.249.11.2
671"DATA",1130580001.101,45,1)
672Diabetes: Hemoglobin A1c Poor Contro
673"DATA",1130580001.101,45,4)
674PQRI-1
675"DATA",1130580001.101,45,5)
676Diabetes: NQF0059 Hemoglobin A1c Poor Control
677"DATA",1130580001.101,45,6,0)
678^^2^2^3110430^
679"DATA",1130580001.101,45,6,1,0)
680Percentage of patients 18 - 75 years of age with diabetes (type 1
681"DATA",1130580001.101,45,6,2,0)
682or type 2) who had hemoglobin A1c > 9.0%.
683"DATA",1130580001.101,45,7)
684NQF0059^^^^^^260^258
685"DATA",1130580001.101,46,0)
686MU EP NQF 0064^^^2.16.840.1.113883.3.249.11.3
687"DATA",1130580001.101,46,1)
688Diabetes: Low Density Lipoprotein (LDL) Management and Control
689"DATA",1130580001.101,46,4)
690PQRI-2
691"DATA",1130580001.101,46,5)
692NQF0064 Diabetes: Low Density Lipoprotein (LDL) Management and Control
693"DATA",1130580001.101,46,6,0)
694^^3^3^3110430^
695"DATA",1130580001.101,46,6,1,0)
696Percentage of patients 18-75 years of age with diabetes (type 1
697"DATA",1130580001.101,46,6,2,0)
698or type 2) who had LDL-C < 100 mg/dL).Percentage of patients 18-75 years
699"DATA",1130580001.101,46,6,3,0)
700of age with diabetes (type 1 or type 2) who had LDL-C < 100 mg/dL).
701"DATA",1130580001.101,46,7)
702NQF0064^^^^^^248^258
703"DATA",1130580001.101,47,0)
704MU EP NQF 0061^^^2.16.840.1.113883.3.249.11.4
705"DATA",1130580001.101,47,1)
706Blood Pressure Management
707"DATA",1130580001.101,47,4)
708PQRI-3
709"DATA",1130580001.101,47,5)
710NQF0061 Diabetes: Blood Pressure Management
711"DATA",1130580001.101,47,6,0)
712^^2^2^3110430^
713"DATA",1130580001.101,47,6,1,0)
714Percentage of patients 18 - 75 years of age with
715"DATA",1130580001.101,47,6,2,0)
716diabetes (type 1 or type 2) who had blood pressure <140/90 mmHg.
717"DATA",1130580001.101,47,7)
718NQF0061^^^^^^262^258
719"DATA",1130580001.101,48,0)
720MU EP NQF 0081^^^2.16.840.1.113883.3.249.11.5
721"DATA",1130580001.101,48,1)
722Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD)
723"DATA",1130580001.101,48,4)
724PQRI-5
725"DATA",1130580001.101,48,5)
726Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD)
727"DATA",1130580001.101,48,6,0)
728^^3^3^3110430^
729"DATA",1130580001.101,48,6,1,0)
730Percentage of patients aged 18 years and older with a
731"DATA",1130580001.101,48,6,2,0)
732diagnosis of heart failure and LVSD (LVEF < 40%) who were
733"DATA",1130580001.101,48,6,3,0)
734prescribed ACE inhibitor or ARB therapy
735"DATA",1130580001.101,48,7)
736NQF0081^^^^
737"DATA",1130580001.101,49,0)
738MU EP NQF 0070^^^2.16.840.1.113883.3.249.11.6
739"DATA",1130580001.101,49,1)
740CMS Measure #7: Coronary Artery Disease (CAD): Beta-Blocker Therapy for CAD Patients with Prior Myocardial Infarction (MI)
741"DATA",1130580001.101,49,4)
742PQRI-7
743"DATA",1130580001.101,49,5)
744Percentage of patients 18 aged 18 years and older wit a diagnosis of CAD and prior MI who were prescribed beta-blocker therapy
745"DATA",1130580001.101,49,6,0)
746^^3^3^3101013^
747"DATA",1130580001.101,49,6,1,0)
748Percentage of patients aged 18 years and older with a diagnosis of
749"DATA",1130580001.101,49,6,2,0)
750coronary artery disease and a prior MI who where prescribed beta-blocker
751"DATA",1130580001.101,49,6,3,0)
752therapy
753"DATA",1130580001.101,49,7)
754NQF0070
755"DATA",1130580001.101,50,0)
756MU EP NQF 0031^^^2.16.840.1.113883.3.249.11.9
757"DATA",1130580001.101,50,1)
758Breast Cancer Screening
759"DATA",1130580001.101,50,4)
760PQRI-112
761"DATA",1130580001.101,50,5)
762Breast Cancer Screening
763"DATA",1130580001.101,50,6,0)
764^^2^2^3110430^
765"DATA",1130580001.101,50,6,1,0)
766Percentage of women 40-69 years of age who had a
767"DATA",1130580001.101,50,6,2,0)
768mammogram to screen for breast cancer
769"DATA",1130580001.101,50,7)
770NQF0031^^^^
771"DATA",1130580001.101,51,0)
772MU EP NQF 0034^^^2.16.840.1.113883.3.249.11.10
773"DATA",1130580001.101,51,1)
774Colorectal Cancer Screening
775"DATA",1130580001.101,51,4)
776PQRI-113
777"DATA",1130580001.101,51,5)
778Colorectal Cancer Screening
779"DATA",1130580001.101,51,6,0)
780^^2^2^3110430^
781"DATA",1130580001.101,51,6,1,0)
782Percentage of adults 50-75 years of age who had appropriate screening for
783"DATA",1130580001.101,51,6,2,0)
784colorectal cancer.
785"DATA",1130580001.101,51,7)
786NQF0034^^^^
787"DATA",1130580001.101,52,0)
788MU EP NQF 0067^^
789"DATA",1130580001.101,52,1)
790Coronary Artery Disease (CAD): Oral Antiplatelet Therapy Prescribed for Patients with CAD
791"DATA",1130580001.101,52,5)
792Coronary Artery Disease (CAD): Oral Antiplatelet Therapy Prescribed for Patients with CAD
793"DATA",1130580001.101,52,6,0)
794^^2^2^3110430^
795"DATA",1130580001.101,52,6,1,0)
796Percentage of patients aged 18 years and older with a
797"DATA",1130580001.101,52,6,2,0)
798diagnosis of CAD who were prescribed oral antiplatelet therapy.
799"DATA",1130580001.101,52,7)
800NQF0067^^^^
801"DATA",1130580001.101,53,0)
802MU EP NQF 0083^^
803"DATA",1130580001.101,53,1)
804Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)
805"DATA",1130580001.101,53,5)
806Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)
807"DATA",1130580001.101,53,6,0)
808^^3^3^3110430^
809"DATA",1130580001.101,53,6,1,0)
810Percentage of patients aged 18 years and older with a
811"DATA",1130580001.101,53,6,2,0)
812diagnosis of heart failure who also have LVSD (LVEF < 40%) and who were
813"DATA",1130580001.101,53,6,3,0)
814prescribed beta-blocker therapy
815"DATA",1130580001.101,53,7)
816NQF0083^^^^
817"DATA",1130580001.101,54,0)
818MU EP NQF 0105^^
819"DATA",1130580001.101,54,1)
820Anti-depressant medication management: (a) Effective Acute Phase Treatment,(b)Effective Continuation Phase Treatment
821"DATA",1130580001.101,54,5)
822Anti-depressant medication management: (a) Effective Acute Phase Treatment,(b)Effective Continuation Phase Treatment
823"DATA",1130580001.101,54,6,0)
824^^4^4^3110430^
825"DATA",1130580001.101,54,6,1,0)
826The percentage of patients 18 years of age and older
827"DATA",1130580001.101,54,6,2,0)
828who were diagnosed with a new episode of major depression, treated
829"DATA",1130580001.101,54,6,3,0)
830with antidepressant medication, and who remained on an
831"DATA",1130580001.101,54,6,4,0)
832antidepressant medication treatment.
833"DATA",1130580001.101,54,7)
834NQF0105^^^^
835"DATA",1130580001.101,55,0)
836MU EP NQF 0086^^
837"DATA",1130580001.101,55,1)
838Primary Open Angle Glaucoma (POAG): Optic Nerve Evaluation
839"DATA",1130580001.101,55,5)
840Primary Open Angle Glaucoma (POAG): Optic Nerve Evaluation
841"DATA",1130580001.101,55,6,0)
842^^4^4^3110430^
843"DATA",1130580001.101,55,6,1,0)
844Percentage of patients aged 18 years and older with a
845"DATA",1130580001.101,55,6,2,0)
846diagnosis of POAG who have been seen for at least two office visits
847"DATA",1130580001.101,55,6,3,0)
848who have an optic nerve head evaluation during one or more office
849"DATA",1130580001.101,55,6,4,0)
850visits within 12 months.
851"DATA",1130580001.101,55,7)
852NQF0086^^^^
853"DATA",1130580001.101,56,0)
854MU EP NQF 0088^^
855"DATA",1130580001.101,56,1)
856Diabetic Retinopathy: Documentation of Presence or Absence of Macular Edema and Level of Severity of Retinopathy
857"DATA",1130580001.101,56,5)
858Diabetic Retinopathy: Documentation of Presence or Absence of Macular Edema and Level of Severity of Retinopathy
859"DATA",1130580001.101,56,6,0)
860^^5^5^3110430^
861"DATA",1130580001.101,56,6,1,0)
862Percentage of patients aged 18 years and older with a
863"DATA",1130580001.101,56,6,2,0)
864diagnosis of diabetic retinopathy who had a dilated macular or fundus
865"DATA",1130580001.101,56,6,3,0)
866exam performed which included documentation of the level of severity
867"DATA",1130580001.101,56,6,4,0)
868of retinopathy and the presence or absence of macular edema during
869"DATA",1130580001.101,56,6,5,0)
870one or more office visits within 12 months.
871"DATA",1130580001.101,56,7)
872NQF0088^^^^
873"DATA",1130580001.101,57,0)
874MU EP NQF 0089^^
875"DATA",1130580001.101,57,1)
876Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care
877"DATA",1130580001.101,57,5)
878Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care
879"DATA",1130580001.101,57,6,0)
880^^6^6^3110430^
881"DATA",1130580001.101,57,6,1,0)
882Percentage of patients aged 18 years and older with a
883"DATA",1130580001.101,57,6,2,0)
884diagnosis of diabetic retinopathy who had a dilated macular or fundus
885"DATA",1130580001.101,57,6,3,0)
886exam performed with documented communication to the physician who
887"DATA",1130580001.101,57,6,4,0)
888manages the ongoing care of the patient with diabetes mellitus
889"DATA",1130580001.101,57,6,5,0)
890regarding the findings of the macular or fundus exam at least once
891"DATA",1130580001.101,57,6,6,0)
892within 12 months.
893"DATA",1130580001.101,57,7)
894NQF0089^^^^
895"DATA",1130580001.101,58,0)
896MU EP NQF 0047^^
897"DATA",1130580001.101,58,1)
898Asthma Pharmacologic Therapy
899"DATA",1130580001.101,58,5)
900Asthma Pharmacologic Therapy
901"DATA",1130580001.101,58,6,0)
902^1130580001.111^4^4^3110430^^
903"DATA",1130580001.101,58,6,1,0)
904Percentage of patients aged 5 through 40 years with a
905"DATA",1130580001.101,58,6,2,0)
906diagnosis of mild, moderate, or severe persistent asthma who were
907"DATA",1130580001.101,58,6,3,0)
908prescribed either the preferred long-term control medication (inhaled
909"DATA",1130580001.101,58,6,4,0)
910corticosteroid) or an acceptable alternative treatment
911"DATA",1130580001.101,58,7)
912NQF0047^^^^
913"DATA",1130580001.101,59,0)
914MU EP NQF 0001^^
915"DATA",1130580001.101,59,1)
916Asthma Assessment
917"DATA",1130580001.101,59,5)
918Asthma Assessment
919"DATA",1130580001.101,59,6,0)
920^^5^5^3110430^
921"DATA",1130580001.101,59,6,1,0)
922Percentage of patients aged 5 through 40 years with a
923"DATA",1130580001.101,59,6,2,0)
924diagnosis of asthma and who have been seen for at least 2 office
925"DATA",1130580001.101,59,6,3,0)
926visits, who were evaluated during at least one office visit within 12
927"DATA",1130580001.101,59,6,4,0)
928months for the frequency (numeric) of daytime and nocturnal asthma
929"DATA",1130580001.101,59,6,5,0)
930symptoms.
931"DATA",1130580001.101,59,7)
932NQF0001^^^^
933"DATA",1130580001.101,60,0)
934MU EP NQF 0002^^
935"DATA",1130580001.101,60,1)
936Oncology Breast Cancer: Hormonal Therapy for Stage IC-IIIC Estrogen Receptor/Progesterone Receptor (ER/PR) Positive Breat Cancer
937"DATA",1130580001.101,60,5)
938Oncology Breast Cancer: Hormonal Therapy for Stage IC-IIIC Estrogen Receptor/Progesterone Receptor (ER/PR) Positive Breast Cancer
939"DATA",1130580001.101,60,6,0)
940^^4^4^3110430^
941"DATA",1130580001.101,60,6,1,0)
942Percentage of female patients aged 18 years and older
943"DATA",1130580001.101,60,6,2,0)
944with Stage IC through IIIC, ER or PR positive breast cancer who were
945"DATA",1130580001.101,60,6,3,0)
946prescribed tamoxifen or aromatase inhibitor (AI) during the 12-month
947"DATA",1130580001.101,60,6,4,0)
948reporting period.
949"DATA",1130580001.101,60,7)
950NQF0002^^^^
951"DATA",1130580001.101,61,0)
952MU EP NQF 0385^^
953"DATA",1130580001.101,61,1)
954Oncology Colon Cancer: Chemotherapy for Stage III Colon Cancer Patients
955"DATA",1130580001.101,61,5)
956Oncology Colon Cancer: Chemotherapy for Stage III Colon Cancer Patients
957"DATA",1130580001.101,61,6,0)
958^^4^4^3110430^
959"DATA",1130580001.101,61,6,1,0)
960Percentage of patients aged 18 years and older with
961"DATA",1130580001.101,61,6,2,0)
962Stage IIIA through IIIC colon cancer who are referred for adjuvant
963"DATA",1130580001.101,61,6,3,0)
964chemotherapy, prescribed adjuvant chemotherapy, or have previously
965"DATA",1130580001.101,61,6,4,0)
966received adjuvant chemotherapy within the 12-month reporting period
967"DATA",1130580001.101,61,7)
968NQF0385^^^^
969"DATA",1130580001.101,62,0)
970MU EP NQF 0389^^
971"DATA",1130580001.101,62,1)
972Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients
973"DATA",1130580001.101,62,5)
974Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients
975"DATA",1130580001.101,62,6,0)
976^^5^5^3110430^
977"DATA",1130580001.101,62,6,1,0)
978Percentage of patients, regardless of age, with a diagnosis of
979"DATA",1130580001.101,62,6,2,0)
980prostate cancer at low risk of recurrence receiving interstitial prostate
981"DATA",1130580001.101,62,6,3,0)
982brachytherapy, OR external beam radiotherapy to the prostate, OR radical
983"DATA",1130580001.101,62,6,4,0)
984prostatectomy, OR cryotherapy who did not have a bone scan performed at
985"DATA",1130580001.101,62,6,5,0)
986any time since diagnosis of prostate cancer.
987"DATA",1130580001.101,62,7)
988NQF0389^^^^
989"DATA",1130580001.101,63,0)
990MU EP NQF 0027^^
991"DATA",1130580001.101,63,1)
992Smoking Smokers and Tobacco Users to Quit,b. Discussing Smoking and Tobacco use Cessation Medications, c. Discussing Smoking and Tobacco use Cessation Strategies and Tobacco Use Cessation, Medical assistance: a. Advising
993"DATA",1130580001.101,63,5)
994Smoking and Tobacco Use Cessation
995"DATA",1130580001.101,63,6,0)
996^^5^5^3110430^
997"DATA",1130580001.101,63,6,1,0)
998Percentage of patients 18 years of age and older who were
999"DATA",1130580001.101,63,6,2,0)
1000current smokers or tobacco users, who were seen by a practitioner during
1001"DATA",1130580001.101,63,6,3,0)
1002the measurement year and who received advice to quit smoking or tobacco
1003"DATA",1130580001.101,63,6,4,0)
1004use or whose practitioner recommended or discussed smoking or tobacco use
1005"DATA",1130580001.101,63,6,5,0)
1006cessation medications, methods or strategies
1007"DATA",1130580001.101,63,7)
1008NQF0027^^^^
1009"DATA",1130580001.101,64,0)
1010MU EP NQF 0055^^
1011"DATA",1130580001.101,64,1)
1012Diabetes: Eye Exam
1013"DATA",1130580001.101,64,5)
1014Diabetes: Eye Exam
1015"DATA",1130580001.101,64,6,0)
1016^^3^3^3110430^
1017"DATA",1130580001.101,64,6,1,0)
1018Percentage of patients 18 -75 years of age with diabetes (type 1
1019"DATA",1130580001.101,64,6,2,0)
1020or type 2) who had a retinal or dilated eye exam or a negative retinal
1021"DATA",1130580001.101,64,6,3,0)
1022exam (no evidence of retinopathy) by an eye care professional
1023"DATA",1130580001.101,64,7)
1024NQF0055^^^^
1025"DATA",1130580001.101,65,0)
1026MU EP NQF 0062^^
1027"DATA",1130580001.101,65,1)
1028Diabetes: Urine Screening
1029"DATA",1130580001.101,65,5)
1030Diabetes: Urine Screening
1031"DATA",1130580001.101,65,6,0)
1032^^3^3^3110430^
1033"DATA",1130580001.101,65,6,1,0)
1034Percentage of patients 18 - 75 years of age with diabetes (type 1
1035"DATA",1130580001.101,65,6,2,0)
1036or type 2) who had a nephropathy screening test or evidence of
1037"DATA",1130580001.101,65,6,3,0)
1038nephropathy.
1039"DATA",1130580001.101,65,7)
1040NQF0062^^^^
1041"DATA",1130580001.101,66,0)
1042MU EP NQF 0056^^
1043"DATA",1130580001.101,66,1)
1044Diabetes: Foot Exam
1045"DATA",1130580001.101,66,5)
1046Diabetes: Foot Exam
1047"DATA",1130580001.101,66,6,0)
1048^^3^3^3110430^
1049"DATA",1130580001.101,66,6,1,0)
1050The percentage of patients aged 18 - 75 years with diabetes
1051"DATA",1130580001.101,66,6,2,0)
1052(type 1 or type 2) who had a foot exam (visual inspection, sensory exam
1053"DATA",1130580001.101,66,6,3,0)
1054with monofilament, or pulse exam).
1055"DATA",1130580001.101,66,7)
1056NQF0056^^^^
1057"DATA",1130580001.101,67,0)
1058MU EP NQF 0074^^
1059"DATA",1130580001.101,67,1)
1060Coronary Artery Disease (CAD): Drug Therapy for Lowering LDLCholesterol
1061"DATA",1130580001.101,67,5)
1062Coronary Artery Disease (CAD): Drug Therapy for Lowering LDLCholesterol
1063"DATA",1130580001.101,67,6,0)
1064^^3^3^3110430^
1065"DATA",1130580001.101,67,6,1,0)
1066Percentage of patients aged 18 years and older with a
1067"DATA",1130580001.101,67,6,2,0)
1068diagnosis of CAD who were prescribed a lipid-lowering therapy (based
1069"DATA",1130580001.101,67,6,3,0)
1070on current ACC/AHA guidelines).
1071"DATA",1130580001.101,67,7)
1072NQF0074^^^^
1073"DATA",1130580001.101,68,0)
1074MU EP NQF 0084^^
1075"DATA",1130580001.101,68,1)
1076Heart Failure (HF): Warfarin Therapy Patients with Atrial Fibrillation
1077"DATA",1130580001.101,68,5)
1078Heart Failure (HF): Warfarin Therapy Patients with Atrial Fibrillation
1079"DATA",1130580001.101,68,6,0)
1080^^3^3^3110430^
1081"DATA",1130580001.101,68,6,1,0)
1082Percentage of all patients aged 18 years and older with a
1083"DATA",1130580001.101,68,6,2,0)
1084diagnosis of heart failure and paroxysmal or chronic atrial fibrillation
1085"DATA",1130580001.101,68,6,3,0)
1086who were prescribed warfarin therapy.
1087"DATA",1130580001.101,68,7)
1088NQF0084^^^^
1089"DATA",1130580001.101,69,0)
1090MU EP NQF 0073^^
1091"DATA",1130580001.101,69,1)
1092Ischemic Vascular Disease (IVD): Blood Pressure Management
1093"DATA",1130580001.101,69,5)
1094Ischemic Vascular Disease (IVD): Blood Pressure Management
1095"DATA",1130580001.101,69,6,0)
1096^^11^11^3110430^
1097"DATA",1130580001.101,69,6,1,0)
1098Percentage of patients 18 years of age and older who
1099"DATA",1130580001.101,69,6,2,0)
1100were discharged alive for acute myocardial infarction (AMI), coronary
1101"DATA",1130580001.101,69,6,3,0)
1102artery bypass graft (CABG) or percutaneous transluminal coronary
1103"DATA",1130580001.101,69,6,4,0)
1104Percentage of patients 18 years of age and older who
1105"DATA",1130580001.101,69,6,5,0)
1106were discharged alive for acute myocardial infarction (AMI), coronary
1107"DATA",1130580001.101,69,6,6,0)
1108artery bypass graft (CABG) or percutaneous transluminal coronary
1109"DATA",1130580001.101,69,6,7,0)
1110angioplasty (PTCA) from January 1- November 1 of the year prior to
1111"DATA",1130580001.101,69,6,8,0)
1112the measurement year, or who had a diagnosis of ischemic vascular
1113"DATA",1130580001.101,69,6,9,0)
1114disease (IVD) during the measurement year and the year prior to the
1115"DATA",1130580001.101,69,6,10,0)
1116measurement year and whose recent blood pressure is in control
1117"DATA",1130580001.101,69,6,11,0)
1118(<140/90 mmHg).
1119"DATA",1130580001.101,69,7)
1120NQF0073^^^^
1121"DATA",1130580001.101,70,0)
1122MU EP NQF 0068^^
1123"DATA",1130580001.101,70,1)
1124Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antithrombotic
1125"DATA",1130580001.101,70,5)
1126 Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antithrombotic
1127"DATA",1130580001.101,70,6,0)
1128^^8^8^3110430^
1129"DATA",1130580001.101,70,6,1,0)
1130 Percentage of patients 18 years of age and older who were
1131"DATA",1130580001.101,70,6,2,0)
1132discharged alive for acute myocardial infarction (AMI), coronary artery
1133"DATA",1130580001.101,70,6,3,0)
1134bypass graft (CABG) or percutaneous transluminal coronary
1135"DATA",1130580001.101,70,6,4,0)
1136angioplasty (PTCA) from January 1-November 1 of the year prior to the
1137"DATA",1130580001.101,70,6,5,0)
1138measurement year, or who had a diagnosis of ischemic vascular
1139"DATA",1130580001.101,70,6,6,0)
1140disease (IVD) during the measurement year and the year prior to the
1141"DATA",1130580001.101,70,6,7,0)
1142measurement year and who had documentation of use of aspirin or
1143"DATA",1130580001.101,70,6,8,0)
1144another antithrombotic during the measurement year
1145"DATA",1130580001.101,70,7)
1146NQF0068^^^^
1147"DATA",1130580001.101,71,0)
1148MU EP NQF 0004^^
1149"DATA",1130580001.101,71,1)
1150 Initiation and Engagement of Alcohol and Other Drug Dependence Treatment:(a)Initiation,(b)Engagement
1151"DATA",1130580001.101,71,5)
1152Initiation and Engagement of Alcohol and Other Drug Dependence Treatment:(a) Initiation,(b) Engagement
1153"DATA",1130580001.101,71,6,0)
1154^^6^6^3110430^
1155"DATA",1130580001.101,71,6,1,0)
1156The percentage of adolescent and adult patients with a new
1157"DATA",1130580001.101,71,6,2,0)
1158episode of alcohol and other drug (AOD) dependence who initiate treatment
1159"DATA",1130580001.101,71,6,3,0)
1160through an inpatient AOD admission, outpatient visit, intensive
1161"DATA",1130580001.101,71,6,4,0)
1162outpatient encounter or partial hospitalization within 14 days of the
1163"DATA",1130580001.101,71,6,5,0)
1164diagnosis and who initiated treatment and who had two or more additional
1165"DATA",1130580001.101,71,6,6,0)
1166services with an AOD diagnosis within 30 days of the initiation visit.
1167"DATA",1130580001.101,71,7)
1168NQF0004^^^^
1169"DATA",1130580001.101,72,0)
1170MU EP NQF 0012^^
1171"DATA",1130580001.101,72,1)
1172Prenatal Care: Screening for Human Immunodeficiency Virus (HIV)
1173"DATA",1130580001.101,72,5)
1174Prenatal Care: Screening for Human Immunodeficiency Virus (HIV)
1175"DATA",1130580001.101,72,6,0)
1176^^3^3^3110430^
1177"DATA",1130580001.101,72,6,1,0)
1178Percentage of patients, regardless of age, who gave birth during
1179"DATA",1130580001.101,72,6,2,0)
1180a 12-month period who were screened for HIV infection during the first or
1181"DATA",1130580001.101,72,6,3,0)
1182second prenatal care visit.
1183"DATA",1130580001.101,72,7)
1184NQF0012^^^^
1185"DATA",1130580001.101,73,0)
1186MU EP NQF 0014^^
1187"DATA",1130580001.101,73,1)
1188Prenatal Care: Anti-D Immune Globulin
1189"DATA",1130580001.101,73,5)
1190Prenatal Care: Anti-D Immune Globulin
1191"DATA",1130580001.101,73,6,0)
1192^^3^3^3110430^
1193"DATA",1130580001.101,73,6,1,0)
1194Percentage of D (Rh) negative, unsensitized patients, regardless
1195"DATA",1130580001.101,73,6,2,0)
1196of age, who gave birth during a 12-month period who received anti-D
1197"DATA",1130580001.101,73,6,3,0)
1198immune globulin at 26-30 weeks gestation.
1199"DATA",1130580001.101,73,7)
1200NQD0014^^^^
1201"DATA",1130580001.101,74,0)
1202MU EP NQF 0018^^
1203"DATA",1130580001.101,74,1)
1204Controlling High Blood Pressure
1205"DATA",1130580001.101,74,5)
1206Controlling High Blood Pressure
1207"DATA",1130580001.101,74,6,0)
1208^^3^3^3110430^
1209"DATA",1130580001.101,74,6,1,0)
1210The percentage of patients 18-85 years of age who had a
1211"DATA",1130580001.101,74,6,2,0)
1212diagnosis of hypertension and whose BP was adequately controlled during
1213"DATA",1130580001.101,74,6,3,0)
1214the measurement year
1215"DATA",1130580001.101,74,7)
1216NQF0018^^^^
1217"DATA",1130580001.101,75,0)
1218MU EP NQF 0032^^
1219"DATA",1130580001.101,75,1)
1220Cervical Cancer Screening
1221"DATA",1130580001.101,75,5)
1222Cervical Cancer Screening
1223"DATA",1130580001.101,75,6,0)
1224^^2^2^3110430^
1225"DATA",1130580001.101,75,6,1,0)
1226Percentage of women 21-64 years of age, who received one or
1227"DATA",1130580001.101,75,6,2,0)
1228more Pap tests to screen for cervical cancer
1229"DATA",1130580001.101,75,7)
1230NQF0032^^^^
1231"DATA",1130580001.101,76,0)
1232MU EP NQF 0033^^
1233"DATA",1130580001.101,76,1)
1234Chlamydia Screening for Women
1235"DATA",1130580001.101,76,5)
1236Chlamydia Screening for Women
1237"DATA",1130580001.101,76,6,0)
1238^^3^3^3110430^
1239"DATA",1130580001.101,76,6,1,0)
1240Percentage of women 15- 24 years of age who were identified as sexually
1241"DATA",1130580001.101,76,6,2,0)
1242active and who had at least one test for chlamydia during the measurement
1243"DATA",1130580001.101,76,6,3,0)
1244year.
1245"DATA",1130580001.101,76,7)
1246NQF0033^^^^
1247"DATA",1130580001.101,77,0)
1248MU EP NQF 0036^^
1249"DATA",1130580001.101,77,1)
1250Use of Appropriate Medications for Asthma
1251"DATA",1130580001.101,77,5)
1252Use of Appropriate Medications for Asthma
1253"DATA",1130580001.101,77,6,0)
1254^^4^4^3110430^
1255"DATA",1130580001.101,77,6,1,0)
1256Percentage of patients 5 - 50 years of age who were identified as having
1257"DATA",1130580001.101,77,6,2,0)
1258persistent asthma and were appropriately prescribed medication during the
1259"DATA",1130580001.101,77,6,3,0)
1260measurement year. Report three age stratifications (5-11 years, 12-50
1261"DATA",1130580001.101,77,6,4,0)
1262years, and total).
1263"DATA",1130580001.101,77,7)
1264NQF0036^^^^
1265"DATA",1130580001.101,78,0)
1266MU EP NQF 0052^^
1267"DATA",1130580001.101,78,1)
1268Low Back Pain: Use of Imaging Studies
1269"DATA",1130580001.101,78,5)
1270Low Back Pain: Use of Imaging Studies
1271"DATA",1130580001.101,78,6,0)
1272^1130580001.111^3^3^3110430^^
1273"DATA",1130580001.101,78,6,1,0)
1274Percentage of patients with a primary diagnosis of low back pain
1275"DATA",1130580001.101,78,6,2,0)
1276who did not have an imaging study (plain x-ray, MRI, CT scan) within 28
1277"DATA",1130580001.101,78,6,3,0)
1278days of diagnosis.
1279"DATA",1130580001.101,78,7)
1280NQF0052^^^^
1281"DATA",1130580001.101,79,0)
1282MU EP NQF 0075^^
1283"DATA",1130580001.101,79,1)
1284Ischemic Vascular Disease (IVD): Complete Lipid Panel and LDL Control
1285"DATA",1130580001.101,79,5)
1286Ischemic Vascular Disease (IVD): Complete Lipid Panel and LDL Control
1287"DATA",1130580001.101,79,6,0)
1288^^7^7^3110430^
1289"DATA",1130580001.101,79,6,1,0)
1290Percentage of patients 18 years of age and older who were discharged alive
1291"DATA",1130580001.101,79,6,2,0)
1292for acute myocardial infarction (AMI), coronary artery bypass graft (CABG)
1293"DATA",1130580001.101,79,6,3,0)
1294or percutaneous transluminal angioplasty (PTCA) from January 1-November1
1295"DATA",1130580001.101,79,6,4,0)
1296of the year prior to the measurement year, or who had a diagnosis of
1297"DATA",1130580001.101,79,6,5,0)
1298ischemic vascular disease (IVD) during the measurement year and the year
1299"DATA",1130580001.101,79,6,6,0)
1300prior to the measurement year and who had a complete lipid profile
1301"DATA",1130580001.101,79,6,7,0)
1302performed during the measurement year and whose LDL-C<100 mg/dL
1303"DATA",1130580001.101,79,7)
1304NQF0075^^^^
1305"DATA",1130580001.101,80,0)
1306MU EP NQF 0575^^
1307"DATA",1130580001.101,80,1)
1308Diabetes: Hemoglobin A1c Control (<8.0%)
1309"DATA",1130580001.101,80,5)
1310Diabetes: Hemoglobin A1c Control (<8.0%)
1311"DATA",1130580001.101,80,6,0)
1312^^2^2^3110430^
1313"DATA",1130580001.101,80,6,1,0)
1314The percentage of patients 18-75 years of age with diabetes
1315"DATA",1130580001.101,80,6,2,0)
1316(type 1 or type 2) who had hemoglobin A1c <8.0%
1317"DATA",1130580001.101,80,7)
1318NQF0575^^^^
1319"DATA",1130580001.101,81,0)
1320MU EP NQF 0028B^^
1321"DATA",1130580001.101,81,1)
1322NQF0028B Preventive Care and Screening Measure Pair: a. Tobacco Use Assessment,b. Tobacco Cessation Intervention
1323"DATA",1130580001.101,81,5)
1324NQF0028B Tobacco Use Assessment and Cessation Intervention
1325"DATA",1130580001.101,81,6,0)
1326^1130580001.111^7^7^3110625^^^^
1327"DATA",1130580001.101,81,6,1,0)
1328 Percentage of patients aged 18 years and
1329"DATA",1130580001.101,81,6,2,0)
1330older who have been seen for at least 2 office visits who
1331"DATA",1130580001.101,81,6,3,0)
1332were queried about tobacco use one or more times within
1333"DATA",1130580001.101,81,6,4,0)
133424 months b. Percentage of patients aged 18 years and
1335"DATA",1130580001.101,81,6,5,0)
1336older identified as tobacco users within the past 24
1337"DATA",1130580001.101,81,6,6,0)
1338months and have been seen for at least 2 office visits,
1339"DATA",1130580001.101,81,6,7,0)
1340who received cessation intervention.
1341"DATA",1130580001.101,81,7)
1342NQF0028B^^^^^^154^160
1343"DATA",1130580001.101,83,0)
1344MU EP NQF 0038 NUM1 DPT^^
1345"DATA",1130580001.101,83,5)
1346NQF0038 NUM1 DPT
1347"DATA",1130580001.101,83,7)
1348NQF0038 NUM1 DPT^^^^^^329^192^11
1349"DATA",1130580001.101,84,0)
1350MU EP NQF 0038 NUM2 IPV^^
1351"DATA",1130580001.101,84,5)
1352NQF0038 NUM2 IPV
1353"DATA",1130580001.101,84,7)
1354NQF0038 NUM2 IPV^^^^^^224^192^11
1355"DATA",1130580001.101,85,0)
1356MU EP NQF 0038 NUM3 MMR^^
1357"DATA",1130580001.101,85,5)
1358NQF0038 NUM3 MMR
1359"DATA",1130580001.101,85,7)
1360NQF0038 NUM3 MMR^^^^^^183^192^11
1361"DATA",1130580001.101,86,0)
1362MU EP NQF 0038 NUM4 HiB^^
1363"DATA",1130580001.101,86,5)
1364NQF0038 NUM4 HiB
1365"DATA",1130580001.101,86,7)
1366NQF0038 NUM4 HiB^^^^^^189^192^11
1367"DATA",1130580001.101,87,0)
1368MU EP NQF 0038 NUM5 HEP B^^
1369"DATA",1130580001.101,87,5)
1370NQF0038 NUM5 HEP B
1371"DATA",1130580001.101,87,7)
1372NQF0038 NUM5 HEP B^^^^^^194^192^11
1373"DATA",1130580001.101,88,0)
1374MU EP NQF 0038 NUM6 VZV^^
1375"DATA",1130580001.101,88,5)
1376NQF0038 NUM6 VZV
1377"DATA",1130580001.101,88,7)
1378NQF0038 NUM6 VZV^^^^^^198^192^11
1379"DATA",1130580001.101,89,0)
1380MU EP NQF 0038 NUM7 PCV^^
1381"DATA",1130580001.101,89,5)
1382NQF0038 NUM7 PCV
1383"DATA",1130580001.101,89,7)
1384NQF0038 NUM7 PCV^^^^^^205^192^11
1385"DATA",1130580001.101,90,0)
1386MU EP NQF 0038 NUM8 HEP A^^
1387"DATA",1130580001.101,90,5)
1388NQF0038 NUM8 HEP A
1389"DATA",1130580001.101,90,7)
1390NQF0038 NUM8 HEP A^^^^^^208^192^11
1391"DATA",1130580001.101,91,0)
1392MU EP NQF 0038 NUM9 RV^^
1393"DATA",1130580001.101,91,5)
1394NQF0038 NUM9
1395"DATA",1130580001.101,91,7)
1396NQF0038 NUM9^^^^^^216^192^11
1397"DATA",1130580001.101,92,0)
1398MU EP NQF 0038 NUM10 FLU^^
1399"DATA",1130580001.101,92,5)
1400NQF0038 NUM10
1401"DATA",1130580001.101,92,7)
1402NQF0038 NUM10^^^^^^331^192^11
1403"DATA",1130580001.101,93,0)
1404MU EP NQF 0038 NUM11 COMBO5^^
1405"DATA",1130580001.101,93,5)
1406NQF0038 NUM11 COMBO5
1407"DATA",1130580001.101,93,7)
1408NQF0038 NUM11 COMBO5^^^^^^228^192^11
1409"DATA",1130580001.101,94,0)
1410MU EP NQF 0038 NUM12 COMBO6^^
1411"DATA",1130580001.101,94,5)
1412NQF0038 NUM12 COMBO6
1413"DATA",1130580001.101,94,7)
1414NQF0038 NUM12 COMBO6^^^^^^231^192^11
1415"DATA",1130580001.101,95,0)
1416MU 2011 INP ADV DIRECTIVES^^
1417"DATA",1130580001.101,95,5)
1418Advance Directives
1419"DATA",1130580001.101,95,7)
1420^^^^
1421"DATA",1130580001.101,96,0)
1422MU 2011 INP CPOE^^
1423"DATA",1130580001.101,96,5)
1424CPOE for Medications
1425"DATA",1130580001.101,96,7)
1426^^^^
1427"DATA",1130580001.101,97,0)
1428MU 2011 INP MED RECON^^
1429"DATA",1130580001.101,97,5)
1430Medication Reconcilliation
1431"DATA",1130580001.101,97,7)
1432^^^^
1433"DATA",1130580001.101,98,0)
1434MU 2011 INP PROBLEM LIST^^
1435"DATA",1130580001.101,98,5)
1436Problem List
1437"DATA",1130580001.101,98,7)
1438^^^^
1439"DATA",1130580001.101,99,0)
1440MU 2011 INP VITAL SIGNS^^
1441"DATA",1130580001.101,99,5)
1442Record Vital Signs
1443"DATA",1130580001.101,99,7)
1444^^^^
1445"DATA",1130580001.101,100,0)
1446MU 2011 INP SMOKING STATUS^^
1447"DATA",1130580001.101,100,5)
1448Smoking Status
1449"DATA",1130580001.101,100,7)
1450^^^^
1451"DATA",1130580001.101,101,0)
1452MU 2011 INP MED LIST^^
1453"DATA",1130580001.101,101,5)
1454Active Medication List
1455"DATA",1130580001.101,101,7)
1456^^^^
1457"DATA",1130580001.101,102,0)
1458MU 2011 INP ALLERGY LIST^^
1459"DATA",1130580001.101,102,5)
1460Medication Allergy List
1461"DATA",1130580001.101,102,7)
1462^^^^
1463"DATA",1130580001.101,103,0)
1464MU 2011 INP DEMOGRAPHICS^^
1465"DATA",1130580001.101,103,5)
1466Record Demographics
1467"DATA",1130580001.101,103,7)
1468^^^^
1469"FIA",1130580001.101)
1470C0Q QUALITY MEASURE
1471"FIA",1130580001.101,0)
1472^C0Q(101,
1473"FIA",1130580001.101,0,0)
14741130580001.101I
1475"FIA",1130580001.101,0,1)
1476y^y^f^^y^^y^o^n
1477"FIA",1130580001.101,0,10)
1478
1479"FIA",1130580001.101,0,11)
1480
1481"FIA",1130580001.101,0,"RLRO")
1482
1483"FIA",1130580001.101,0,"VR")
14841.0^C0Q
1485"FIA",1130580001.101,1130580001.101)
14860
1487"FIA",1130580001.101,1130580001.111)
14880
1489"FRV1",1130580001.101,"23,7",7)
1490MU ED-1 NUMER RS
1491"FRV1",1130580001.101,"23,7",7,"F")
1492;PXRM(810.4,
1493"FRV1",1130580001.101,"23,7",8)
1494MU ED-1 DENOM RS
1495"FRV1",1130580001.101,"23,7",8,"F")
1496;PXRM(810.4,
1497"FRV1",1130580001.101,"24,7",7)
1498MU ED-2 NUMER RS
1499"FRV1",1130580001.101,"24,7",7,"F")
1500;PXRM(810.4,
1501"FRV1",1130580001.101,"24,7",8)
1502MU ED-2 DENOM RS
1503"FRV1",1130580001.101,"24,7",8,"F")
1504;PXRM(810.4,
1505"FRV1",1130580001.101,"25,7",7)
1506MU STK-2 NUMER RS
1507"FRV1",1130580001.101,"25,7",7,"F")
1508;PXRM(810.4,
1509"FRV1",1130580001.101,"25,7",8)
1510MU STK-2 DENOM RS
1511"FRV1",1130580001.101,"25,7",8,"F")
1512;PXRM(810.4,
1513"FRV1",1130580001.101,"26,7",7)
1514MU STK-3 NUMER RS
1515"FRV1",1130580001.101,"26,7",7,"F")
1516;PXRM(810.4,
1517"FRV1",1130580001.101,"26,7",8)
1518MU STK-3 DENOM RS
1519"FRV1",1130580001.101,"26,7",8,"F")
1520;PXRM(810.4,
1521"FRV1",1130580001.101,"27,7",7)
1522MU STK-4 NUMER RS
1523"FRV1",1130580001.101,"27,7",7,"F")
1524;PXRM(810.4,
1525"FRV1",1130580001.101,"27,7",8)
1526MU STK-4 DENOM RS
1527"FRV1",1130580001.101,"27,7",8,"F")
1528;PXRM(810.4,
1529"FRV1",1130580001.101,"28,7",7)
1530MU STK-5 NUMER RS
1531"FRV1",1130580001.101,"28,7",7,"F")
1532;PXRM(810.4,
1533"FRV1",1130580001.101,"28,7",8)
1534MU STK-5 DENOM RS
1535"FRV1",1130580001.101,"28,7",8,"F")
1536;PXRM(810.4,
1537"FRV1",1130580001.101,"29,7",7)
1538MU STK-6 NUMER RS
1539"FRV1",1130580001.101,"29,7",7,"F")
1540;PXRM(810.4,
1541"FRV1",1130580001.101,"29,7",8)
1542MU STK-6 DENOM RS
1543"FRV1",1130580001.101,"29,7",8,"F")
1544;PXRM(810.4,
1545"FRV1",1130580001.101,"30,7",7)
1546MU STK-8 NUMER RS
1547"FRV1",1130580001.101,"30,7",7,"F")
1548;PXRM(810.4,
1549"FRV1",1130580001.101,"30,7",8)
1550MU STK-8 DENOM RS
1551"FRV1",1130580001.101,"30,7",8,"F")
1552;PXRM(810.4,
1553"FRV1",1130580001.101,"31,7",7)
1554MU STK-10 NUMER RS
1555"FRV1",1130580001.101,"31,7",7,"F")
1556;PXRM(810.4,
1557"FRV1",1130580001.101,"31,7",8)
1558MU STK-10 DENOM RS
1559"FRV1",1130580001.101,"31,7",8,"F")
1560;PXRM(810.4,
1561"FRV1",1130580001.101,"32,7",7)
1562MU VTE-1 NUMER RS
1563"FRV1",1130580001.101,"32,7",7,"F")
1564;PXRM(810.4,
1565"FRV1",1130580001.101,"32,7",8)
1566MU VTE-1 DENOM RS
1567"FRV1",1130580001.101,"32,7",8,"F")
1568;PXRM(810.4,
1569"FRV1",1130580001.101,"33,7",7)
1570MU VTE-2 NUMER RS
1571"FRV1",1130580001.101,"33,7",7,"F")
1572;PXRM(810.4,
1573"FRV1",1130580001.101,"33,7",8)
1574MU VTE-2 DENOM RS
1575"FRV1",1130580001.101,"33,7",8,"F")
1576;PXRM(810.4,
1577"FRV1",1130580001.101,"34,7",7)
1578MU VTE-3 NUMER RS
1579"FRV1",1130580001.101,"34,7",7,"F")
1580;PXRM(810.4,
1581"FRV1",1130580001.101,"34,7",8)
1582MU VTE-3 DENOM RS
1583"FRV1",1130580001.101,"34,7",8,"F")
1584;PXRM(810.4,
1585"FRV1",1130580001.101,"35,7",7)
1586MU VTE-4 NUMER RS
1587"FRV1",1130580001.101,"35,7",7,"F")
1588;PXRM(810.4,
1589"FRV1",1130580001.101,"35,7",8)
1590MU VTE-4 DENOM RS
1591"FRV1",1130580001.101,"35,7",8,"F")
1592;PXRM(810.4,
1593"FRV1",1130580001.101,"36,7",7)
1594MU VTE-5 NUMER RS
1595"FRV1",1130580001.101,"36,7",7,"F")
1596;PXRM(810.4,
1597"FRV1",1130580001.101,"36,7",8)
1598MU VTE-5 DENOM RS
1599"FRV1",1130580001.101,"36,7",8,"F")
1600;PXRM(810.4,
1601"FRV1",1130580001.101,"37,7",7)
1602MU VTE-6 NUMER RS
1603"FRV1",1130580001.101,"37,7",7,"F")
1604;PXRM(810.4,
1605"FRV1",1130580001.101,"37,7",8)
1606MU VTE-6 DENOM RS
1607"FRV1",1130580001.101,"37,7",8,"F")
1608;PXRM(810.4,
1609"FRV1",1130580001.101,"39,7",7)
1610MU NQF0421 BMI NUM ALL RS
1611"FRV1",1130580001.101,"39,7",7,"F")
1612;PXRM(810.4,
1613"FRV1",1130580001.101,"39,7",8)
1614MU NQF0421 BMI DENOM ALL RS
1615"FRV1",1130580001.101,"39,7",8,"F")
1616;PXRM(810.4,
1617"FRV1",1130580001.101,"39,7",9)
1618MU NQF0421 ADULT BMI
1619"FRV1",1130580001.101,"39,7",9,"F")
1620;PXRM(810.2,
1621"FRV1",1130580001.101,"40,7",7)
1622MU NQF0013 HTN NUMER2 RS
1623"FRV1",1130580001.101,"40,7",7,"F")
1624;PXRM(810.4,
1625"FRV1",1130580001.101,"40,7",8)
1626MU NQF0013 HTN DENOM2 RS
1627"FRV1",1130580001.101,"40,7",8,"F")
1628;PXRM(810.4,
1629"FRV1",1130580001.101,"41,7",7)
1630MU NQF0028A TOBACCO SCREEN NUM RS
1631"FRV1",1130580001.101,"41,7",7,"F")
1632;PXRM(810.4,
1633"FRV1",1130580001.101,"41,7",8)
1634MU NQF0028B TOBACCO INTERV DENOM RS
1635"FRV1",1130580001.101,"41,7",8,"F")
1636;PXRM(810.4,
1637"FRV1",1130580001.101,"42,7",7)
1638MU NQF0041 FLU RS
1639"FRV1",1130580001.101,"42,7",7,"F")
1640;PXRM(810.4,
1641"FRV1",1130580001.101,"42,7",8)
1642MU NQF0041 FLU DENOM RS
1643"FRV1",1130580001.101,"42,7",8,"F")
1644;PXRM(810.4,
1645"FRV1",1130580001.101,"43,7",7)
1646MU NQF0024 BMI 2-17YR NUM RS
1647"FRV1",1130580001.101,"43,7",7,"F")
1648;PXRM(810.4,
1649"FRV1",1130580001.101,"43,7",8)
1650MU NQF0024 BMI 2-17YRS DEM RS
1651"FRV1",1130580001.101,"43,7",8,"F")
1652;PXRM(810.4,
1653"FRV1",1130580001.101,"45,7",7)
1654MU NQF0059 HBA1C NUM RS
1655"FRV1",1130580001.101,"45,7",7,"F")
1656;PXRM(810.4,
1657"FRV1",1130580001.101,"45,7",8)
1658MU NQF0059 DM DENOM-ALL RS
1659"FRV1",1130580001.101,"45,7",8,"F")
1660;PXRM(810.4,
1661"FRV1",1130580001.101,"46,7",7)
1662MU NQF0064 NUM LDL RS
1663"FRV1",1130580001.101,"46,7",7,"F")
1664;PXRM(810.4,
1665"FRV1",1130580001.101,"46,7",8)
1666MU NQF0059 DM DENOM-ALL RS
1667"FRV1",1130580001.101,"46,7",8,"F")
1668;PXRM(810.4,
1669"FRV1",1130580001.101,"47,7",7)
1670MU NQF0061 NUM DM BP<140/90 RS
1671"FRV1",1130580001.101,"47,7",7,"F")
1672;PXRM(810.4,
1673"FRV1",1130580001.101,"47,7",8)
1674MU NQF0059 DM DENOM-ALL RS
1675"FRV1",1130580001.101,"47,7",8,"F")
1676;PXRM(810.4,
1677"FRV1",1130580001.101,"81,7",7)
1678MU NQF0028B TOBACCO INTERV NUM2 RS
1679"FRV1",1130580001.101,"81,7",7,"F")
1680;PXRM(810.4,
1681"FRV1",1130580001.101,"81,7",8)
1682MU NQF0028B TOBACCO INTERV DENOM RS
1683"FRV1",1130580001.101,"81,7",8,"F")
1684;PXRM(810.4,
1685"FRV1",1130580001.101,"83,7",7)
1686MU NQF0038 NUM1 DPT RS
1687"FRV1",1130580001.101,"83,7",7,"F")
1688;PXRM(810.4,
1689"FRV1",1130580001.101,"83,7",8)
1690MU NQF0038 DENOM RS
1691"FRV1",1130580001.101,"83,7",8,"F")
1692;PXRM(810.4,
1693"FRV1",1130580001.101,"83,7",9)
1694MU NQF0038 CHILDREN'S IMMUNIZATIONS
1695"FRV1",1130580001.101,"83,7",9,"F")
1696;PXRM(810.2,
1697"FRV1",1130580001.101,"84,7",7)
1698MU NQF0038 NUM2 IPV RS
1699"FRV1",1130580001.101,"84,7",7,"F")
1700;PXRM(810.4,
1701"FRV1",1130580001.101,"84,7",8)
1702MU NQF0038 DENOM RS
1703"FRV1",1130580001.101,"84,7",8,"F")
1704;PXRM(810.4,
1705"FRV1",1130580001.101,"84,7",9)
1706MU NQF0038 CHILDREN'S IMMUNIZATIONS
1707"FRV1",1130580001.101,"84,7",9,"F")
1708;PXRM(810.2,
1709"FRV1",1130580001.101,"85,7",7)
1710MU NQF0038 NUM3-ALL RS
1711"FRV1",1130580001.101,"85,7",7,"F")
1712;PXRM(810.4,
1713"FRV1",1130580001.101,"85,7",8)
1714MU NQF0038 DENOM RS
1715"FRV1",1130580001.101,"85,7",8,"F")
1716;PXRM(810.4,
1717"FRV1",1130580001.101,"85,7",9)
1718MU NQF0038 CHILDREN'S IMMUNIZATIONS
1719"FRV1",1130580001.101,"85,7",9,"F")
1720;PXRM(810.2,
1721"FRV1",1130580001.101,"86,7",7)
1722MU NQF0038 NUM4 HIB RS
1723"FRV1",1130580001.101,"86,7",7,"F")
1724;PXRM(810.4,
1725"FRV1",1130580001.101,"86,7",8)
1726MU NQF0038 DENOM RS
1727"FRV1",1130580001.101,"86,7",8,"F")
1728;PXRM(810.4,
1729"FRV1",1130580001.101,"86,7",9)
1730MU NQF0038 CHILDREN'S IMMUNIZATIONS
1731"FRV1",1130580001.101,"86,7",9,"F")
1732;PXRM(810.2,
1733"FRV1",1130580001.101,"87,7",7)
1734MU NQF0038 NUM5 RS
1735"FRV1",1130580001.101,"87,7",7,"F")
1736;PXRM(810.4,
1737"FRV1",1130580001.101,"87,7",8)
1738MU NQF0038 DENOM RS
1739"FRV1",1130580001.101,"87,7",8,"F")
1740;PXRM(810.4,
1741"FRV1",1130580001.101,"87,7",9)
1742MU NQF0038 CHILDREN'S IMMUNIZATIONS
1743"FRV1",1130580001.101,"87,7",9,"F")
1744;PXRM(810.2,
1745"FRV1",1130580001.101,"88,7",7)
1746MU NQF0038 NUM6 VZV RS
1747"FRV1",1130580001.101,"88,7",7,"F")
1748;PXRM(810.4,
1749"FRV1",1130580001.101,"88,7",8)
1750MU NQF0038 DENOM RS
1751"FRV1",1130580001.101,"88,7",8,"F")
1752;PXRM(810.4,
1753"FRV1",1130580001.101,"88,7",9)
1754MU NQF0038 CHILDREN'S IMMUNIZATIONS
1755"FRV1",1130580001.101,"88,7",9,"F")
1756;PXRM(810.2,
1757"FRV1",1130580001.101,"89,7",7)
1758MU NQF0038 NUM7 PCV RS
1759"FRV1",1130580001.101,"89,7",7,"F")
1760;PXRM(810.4,
1761"FRV1",1130580001.101,"89,7",8)
1762MU NQF0038 DENOM RS
1763"FRV1",1130580001.101,"89,7",8,"F")
1764;PXRM(810.4,
1765"FRV1",1130580001.101,"89,7",9)
1766MU NQF0038 CHILDREN'S IMMUNIZATIONS
1767"FRV1",1130580001.101,"89,7",9,"F")
1768;PXRM(810.2,
1769"FRV1",1130580001.101,"90,7",7)
1770MU NQF0038 NUM8 HEP A RS
1771"FRV1",1130580001.101,"90,7",7,"F")
1772;PXRM(810.4,
1773"FRV1",1130580001.101,"90,7",8)
1774MU NQF0038 DENOM RS
1775"FRV1",1130580001.101,"90,7",8,"F")
1776;PXRM(810.4,
1777"FRV1",1130580001.101,"90,7",9)
1778MU NQF0038 CHILDREN'S IMMUNIZATIONS
1779"FRV1",1130580001.101,"90,7",9,"F")
1780;PXRM(810.2,
1781"FRV1",1130580001.101,"91,7",7)
1782MU NQF0038 NUM9 RV RS
1783"FRV1",1130580001.101,"91,7",7,"F")
1784;PXRM(810.4,
1785"FRV1",1130580001.101,"91,7",8)
1786MU NQF0038 DENOM RS
1787"FRV1",1130580001.101,"91,7",8,"F")
1788;PXRM(810.4,
1789"FRV1",1130580001.101,"91,7",9)
1790MU NQF0038 CHILDREN'S IMMUNIZATIONS
1791"FRV1",1130580001.101,"91,7",9,"F")
1792;PXRM(810.2,
1793"FRV1",1130580001.101,"92,7",7)
1794MU NQF0038 NUM10 INFLUENZA RS
1795"FRV1",1130580001.101,"92,7",7,"F")
1796;PXRM(810.4,
1797"FRV1",1130580001.101,"92,7",8)
1798MU NQF0038 DENOM RS
1799"FRV1",1130580001.101,"92,7",8,"F")
1800;PXRM(810.4,
1801"FRV1",1130580001.101,"92,7",9)
1802MU NQF0038 CHILDREN'S IMMUNIZATIONS
1803"FRV1",1130580001.101,"92,7",9,"F")
1804;PXRM(810.2,
1805"FRV1",1130580001.101,"93,7",7)
1806MU NQF0038 NUM11 COMBO5 RS
1807"FRV1",1130580001.101,"93,7",7,"F")
1808;PXRM(810.4,
1809"FRV1",1130580001.101,"93,7",8)
1810MU NQF0038 DENOM RS
1811"FRV1",1130580001.101,"93,7",8,"F")
1812;PXRM(810.4,
1813"FRV1",1130580001.101,"93,7",9)
1814MU NQF0038 CHILDREN'S IMMUNIZATIONS
1815"FRV1",1130580001.101,"93,7",9,"F")
1816;PXRM(810.2,
1817"FRV1",1130580001.101,"94,7",7)
1818MU NQF0038 NUM12 COMBO6 RS
1819"FRV1",1130580001.101,"94,7",7,"F")
1820;PXRM(810.4,
1821"FRV1",1130580001.101,"94,7",8)
1822MU NQF0038 DENOM RS
1823"FRV1",1130580001.101,"94,7",8,"F")
1824;PXRM(810.4,
1825"FRV1",1130580001.101,"94,7",9)
1826MU NQF0038 CHILDREN'S IMMUNIZATIONS
1827"FRV1",1130580001.101,"94,7",9,"F")
1828;PXRM(810.2,
1829"FRV1K",1130580001.101,"23,7",7)
1830B
1831"FRV1K",1130580001.101,"23,7",7,1)
1832MU ED-1 NUMER RS
1833"FRV1K",1130580001.101,"23,7",8)
1834B
1835"FRV1K",1130580001.101,"23,7",8,1)
1836MU ED-1 DENOM RS
1837"FRV1K",1130580001.101,"24,7",7)
1838B
1839"FRV1K",1130580001.101,"24,7",7,1)
1840MU ED-2 NUMER RS
1841"FRV1K",1130580001.101,"24,7",8)
1842B
1843"FRV1K",1130580001.101,"24,7",8,1)
1844MU ED-2 DENOM RS
1845"FRV1K",1130580001.101,"25,7",7)
1846B
1847"FRV1K",1130580001.101,"25,7",7,1)
1848MU STK-2 NUMER RS
1849"FRV1K",1130580001.101,"25,7",8)
1850B
1851"FRV1K",1130580001.101,"25,7",8,1)
1852MU STK-2 DENOM RS
1853"FRV1K",1130580001.101,"26,7",7)
1854B
1855"FRV1K",1130580001.101,"26,7",7,1)
1856MU STK-3 NUMER RS
1857"FRV1K",1130580001.101,"26,7",8)
1858B
1859"FRV1K",1130580001.101,"26,7",8,1)
1860MU STK-3 DENOM RS
1861"FRV1K",1130580001.101,"27,7",7)
1862B
1863"FRV1K",1130580001.101,"27,7",7,1)
1864MU STK-4 NUMER RS
1865"FRV1K",1130580001.101,"27,7",8)
1866B
1867"FRV1K",1130580001.101,"27,7",8,1)
1868MU STK-4 DENOM RS
1869"FRV1K",1130580001.101,"28,7",7)
1870B
1871"FRV1K",1130580001.101,"28,7",7,1)
1872MU STK-5 NUMER RS
1873"FRV1K",1130580001.101,"28,7",8)
1874B
1875"FRV1K",1130580001.101,"28,7",8,1)
1876MU STK-5 DENOM RS
1877"FRV1K",1130580001.101,"29,7",7)
1878B
1879"FRV1K",1130580001.101,"29,7",7,1)
1880MU STK-6 NUMER RS
1881"FRV1K",1130580001.101,"29,7",8)
1882B
1883"FRV1K",1130580001.101,"29,7",8,1)
1884MU STK-6 DENOM RS
1885"FRV1K",1130580001.101,"30,7",7)
1886B
1887"FRV1K",1130580001.101,"30,7",7,1)
1888MU STK-8 NUMER RS
1889"FRV1K",1130580001.101,"30,7",8)
1890B
1891"FRV1K",1130580001.101,"30,7",8,1)
1892MU STK-8 DENOM RS
1893"FRV1K",1130580001.101,"31,7",7)
1894B
1895"FRV1K",1130580001.101,"31,7",7,1)
1896MU STK-10 NUMER RS
1897"FRV1K",1130580001.101,"31,7",8)
1898B
1899"FRV1K",1130580001.101,"31,7",8,1)
1900MU STK-10 DENOM RS
1901"FRV1K",1130580001.101,"32,7",7)
1902B
1903"FRV1K",1130580001.101,"32,7",7,1)
1904MU VTE-1 NUMER RS
1905"FRV1K",1130580001.101,"32,7",8)
1906B
1907"FRV1K",1130580001.101,"32,7",8,1)
1908MU VTE-1 DENOM RS
1909"FRV1K",1130580001.101,"33,7",7)
1910B
1911"FRV1K",1130580001.101,"33,7",7,1)
1912MU VTE-2 NUMER RS
1913"FRV1K",1130580001.101,"33,7",8)
1914B
1915"FRV1K",1130580001.101,"33,7",8,1)
1916MU VTE-2 DENOM RS
1917"FRV1K",1130580001.101,"34,7",7)
1918B
1919"FRV1K",1130580001.101,"34,7",7,1)
1920MU VTE-3 NUMER RS
1921"FRV1K",1130580001.101,"34,7",8)
1922B
1923"FRV1K",1130580001.101,"34,7",8,1)
1924MU VTE-3 DENOM RS
1925"FRV1K",1130580001.101,"35,7",7)
1926B
1927"FRV1K",1130580001.101,"35,7",7,1)
1928MU VTE-4 NUMER RS
1929"FRV1K",1130580001.101,"35,7",8)
1930B
1931"FRV1K",1130580001.101,"35,7",8,1)
1932MU VTE-4 DENOM RS
1933"FRV1K",1130580001.101,"36,7",7)
1934B
1935"FRV1K",1130580001.101,"36,7",7,1)
1936MU VTE-5 NUMER RS
1937"FRV1K",1130580001.101,"36,7",8)
1938B
1939"FRV1K",1130580001.101,"36,7",8,1)
1940MU VTE-5 DENOM RS
1941"FRV1K",1130580001.101,"37,7",7)
1942B
1943"FRV1K",1130580001.101,"37,7",7,1)
1944MU VTE-6 NUMER RS
1945"FRV1K",1130580001.101,"37,7",8)
1946B
1947"FRV1K",1130580001.101,"37,7",8,1)
1948MU VTE-6 DENOM RS
1949"FRV1K",1130580001.101,"39,7",7)
1950B
1951"FRV1K",1130580001.101,"39,7",7,1)
1952MU NQF0421 BMI NUM ALL RS
1953"FRV1K",1130580001.101,"39,7",8)
1954B
1955"FRV1K",1130580001.101,"39,7",8,1)
1956MU NQF0421 BMI DENOM ALL RS
1957"FRV1K",1130580001.101,"39,7",9)
1958B
1959"FRV1K",1130580001.101,"39,7",9,1)
1960MU NQF0421 ADULT BMI
1961"FRV1K",1130580001.101,"40,7",7)
1962B
1963"FRV1K",1130580001.101,"40,7",7,1)
1964MU NQF0013 HTN NUMER2 RS
1965"FRV1K",1130580001.101,"40,7",8)
1966B
1967"FRV1K",1130580001.101,"40,7",8,1)
1968MU NQF0013 HTN DENOM2 RS
1969"FRV1K",1130580001.101,"41,7",7)
1970B
1971"FRV1K",1130580001.101,"41,7",7,1)
1972MU NQF0028A TOBACCO SCREEN NUM RS
1973"FRV1K",1130580001.101,"41,7",8)
1974B
1975"FRV1K",1130580001.101,"41,7",8,1)
1976MU NQF0028B TOBACCO INTERV DENOM RS
1977"FRV1K",1130580001.101,"42,7",7)
1978B
1979"FRV1K",1130580001.101,"42,7",7,1)
1980MU NQF0041 FLU RS
1981"FRV1K",1130580001.101,"42,7",8)
1982B
1983"FRV1K",1130580001.101,"42,7",8,1)
1984MU NQF0041 FLU DENOM RS
1985"FRV1K",1130580001.101,"43,7",7)
1986B
1987"FRV1K",1130580001.101,"43,7",7,1)
1988MU NQF0024 BMI 2-17YR NUM RS
1989"FRV1K",1130580001.101,"43,7",8)
1990B
1991"FRV1K",1130580001.101,"43,7",8,1)
1992MU NQF0024 BMI 2-17YRS DEM RS
1993"FRV1K",1130580001.101,"45,7",7)
1994B
1995"FRV1K",1130580001.101,"45,7",7,1)
1996MU NQF0059 HBA1C NUM RS
1997"FRV1K",1130580001.101,"45,7",8)
1998B
1999"FRV1K",1130580001.101,"45,7",8,1)
2000MU NQF0059 DM DENOM-ALL RS
2001"FRV1K",1130580001.101,"46,7",7)
2002B
2003"FRV1K",1130580001.101,"46,7",7,1)
2004MU NQF0064 NUM LDL RS
2005"FRV1K",1130580001.101,"46,7",8)
2006B
2007"FRV1K",1130580001.101,"46,7",8,1)
2008MU NQF0059 DM DENOM-ALL RS
2009"FRV1K",1130580001.101,"47,7",7)
2010B
2011"FRV1K",1130580001.101,"47,7",7,1)
2012MU NQF0061 NUM DM BP<140/90 RS
2013"FRV1K",1130580001.101,"47,7",8)
2014B
2015"FRV1K",1130580001.101,"47,7",8,1)
2016MU NQF0059 DM DENOM-ALL RS
2017"FRV1K",1130580001.101,"81,7",7)
2018B
2019"FRV1K",1130580001.101,"81,7",7,1)
2020MU NQF0028B TOBACCO INTERV NUM2 RS
2021"FRV1K",1130580001.101,"81,7",8)
2022B
2023"FRV1K",1130580001.101,"81,7",8,1)
2024MU NQF0028B TOBACCO INTERV DENOM RS
2025"FRV1K",1130580001.101,"83,7",7)
2026B
2027"FRV1K",1130580001.101,"83,7",7,1)
2028MU NQF0038 NUM1 DPT RS
2029"FRV1K",1130580001.101,"83,7",8)
2030B
2031"FRV1K",1130580001.101,"83,7",8,1)
2032MU NQF0038 DENOM RS
2033"FRV1K",1130580001.101,"83,7",9)
2034B
2035"FRV1K",1130580001.101,"83,7",9,1)
2036MU NQF0038 CHILDREN'S IMMUNIZATIONS
2037"FRV1K",1130580001.101,"84,7",7)
2038B
2039"FRV1K",1130580001.101,"84,7",7,1)
2040MU NQF0038 NUM2 IPV RS
2041"FRV1K",1130580001.101,"84,7",8)
2042B
2043"FRV1K",1130580001.101,"84,7",8,1)
2044MU NQF0038 DENOM RS
2045"FRV1K",1130580001.101,"84,7",9)
2046B
2047"FRV1K",1130580001.101,"84,7",9,1)
2048MU NQF0038 CHILDREN'S IMMUNIZATIONS
2049"FRV1K",1130580001.101,"85,7",7)
2050B
2051"FRV1K",1130580001.101,"85,7",7,1)
2052MU NQF0038 NUM3-ALL RS
2053"FRV1K",1130580001.101,"85,7",8)
2054B
2055"FRV1K",1130580001.101,"85,7",8,1)
2056MU NQF0038 DENOM RS
2057"FRV1K",1130580001.101,"85,7",9)
2058B
2059"FRV1K",1130580001.101,"85,7",9,1)
2060MU NQF0038 CHILDREN'S IMMUNIZATIONS
2061"FRV1K",1130580001.101,"86,7",7)
2062B
2063"FRV1K",1130580001.101,"86,7",7,1)
2064MU NQF0038 NUM4 HIB RS
2065"FRV1K",1130580001.101,"86,7",8)
2066B
2067"FRV1K",1130580001.101,"86,7",8,1)
2068MU NQF0038 DENOM RS
2069"FRV1K",1130580001.101,"86,7",9)
2070B
2071"FRV1K",1130580001.101,"86,7",9,1)
2072MU NQF0038 CHILDREN'S IMMUNIZATIONS
2073"FRV1K",1130580001.101,"87,7",7)
2074B
2075"FRV1K",1130580001.101,"87,7",7,1)
2076MU NQF0038 NUM5 RS
2077"FRV1K",1130580001.101,"87,7",8)
2078B
2079"FRV1K",1130580001.101,"87,7",8,1)
2080MU NQF0038 DENOM RS
2081"FRV1K",1130580001.101,"87,7",9)
2082B
2083"FRV1K",1130580001.101,"87,7",9,1)
2084MU NQF0038 CHILDREN'S IMMUNIZATIONS
2085"FRV1K",1130580001.101,"88,7",7)
2086B
2087"FRV1K",1130580001.101,"88,7",7,1)
2088MU NQF0038 NUM6 VZV RS
2089"FRV1K",1130580001.101,"88,7",8)
2090B
2091"FRV1K",1130580001.101,"88,7",8,1)
2092MU NQF0038 DENOM RS
2093"FRV1K",1130580001.101,"88,7",9)
2094B
2095"FRV1K",1130580001.101,"88,7",9,1)
2096MU NQF0038 CHILDREN'S IMMUNIZATIONS
2097"FRV1K",1130580001.101,"89,7",7)
2098B
2099"FRV1K",1130580001.101,"89,7",7,1)
2100MU NQF0038 NUM7 PCV RS
2101"FRV1K",1130580001.101,"89,7",8)
2102B
2103"FRV1K",1130580001.101,"89,7",8,1)
2104MU NQF0038 DENOM RS
2105"FRV1K",1130580001.101,"89,7",9)
2106B
2107"FRV1K",1130580001.101,"89,7",9,1)
2108MU NQF0038 CHILDREN'S IMMUNIZATIONS
2109"FRV1K",1130580001.101,"90,7",7)
2110B
2111"FRV1K",1130580001.101,"90,7",7,1)
2112MU NQF0038 NUM8 HEP A RS
2113"FRV1K",1130580001.101,"90,7",8)
2114B
2115"FRV1K",1130580001.101,"90,7",8,1)
2116MU NQF0038 DENOM RS
2117"FRV1K",1130580001.101,"90,7",9)
2118B
2119"FRV1K",1130580001.101,"90,7",9,1)
2120MU NQF0038 CHILDREN'S IMMUNIZATIONS
2121"FRV1K",1130580001.101,"91,7",7)
2122B
2123"FRV1K",1130580001.101,"91,7",7,1)
2124MU NQF0038 NUM9 RV RS
2125"FRV1K",1130580001.101,"91,7",8)
2126B
2127"FRV1K",1130580001.101,"91,7",8,1)
2128MU NQF0038 DENOM RS
2129"FRV1K",1130580001.101,"91,7",9)
2130B
2131"FRV1K",1130580001.101,"91,7",9,1)
2132MU NQF0038 CHILDREN'S IMMUNIZATIONS
2133"FRV1K",1130580001.101,"92,7",7)
2134B
2135"FRV1K",1130580001.101,"92,7",7,1)
2136MU NQF0038 NUM10 INFLUENZA RS
2137"FRV1K",1130580001.101,"92,7",8)
2138B
2139"FRV1K",1130580001.101,"92,7",8,1)
2140MU NQF0038 DENOM RS
2141"FRV1K",1130580001.101,"92,7",9)
2142B
2143"FRV1K",1130580001.101,"92,7",9,1)
2144MU NQF0038 CHILDREN'S IMMUNIZATIONS
2145"FRV1K",1130580001.101,"93,7",7)
2146B
2147"FRV1K",1130580001.101,"93,7",7,1)
2148MU NQF0038 NUM11 COMBO5 RS
2149"FRV1K",1130580001.101,"93,7",8)
2150B
2151"FRV1K",1130580001.101,"93,7",8,1)
2152MU NQF0038 DENOM RS
2153"FRV1K",1130580001.101,"93,7",9)
2154B
2155"FRV1K",1130580001.101,"93,7",9,1)
2156MU NQF0038 CHILDREN'S IMMUNIZATIONS
2157"FRV1K",1130580001.101,"94,7",7)
2158B
2159"FRV1K",1130580001.101,"94,7",7,1)
2160MU NQF0038 NUM12 COMBO6 RS
2161"FRV1K",1130580001.101,"94,7",8)
2162B
2163"FRV1K",1130580001.101,"94,7",8,1)
2164MU NQF0038 DENOM RS
2165"FRV1K",1130580001.101,"94,7",9)
2166B
2167"FRV1K",1130580001.101,"94,7",9,1)
2168MU NQF0038 CHILDREN'S IMMUNIZATIONS
2169"IX",1130580001.101,1130580001.101,"MU",0)
21701130580001.101^MU^MEANINGFUL USE YEAR KEY^R^^F^IR^I^1130580001.101^^^^^LS
2171"IX",1130580001.101,1130580001.101,"MU",1)
2172S ^C0Q(101,"MU",$E(X,1,30),DA)=""
2173"IX",1130580001.101,1130580001.101,"MU",2)
2174K ^C0Q(101,"MU",$E(X,1,30),DA)
2175"IX",1130580001.101,1130580001.101,"MU",2.5)
2176K ^C0Q(101,"MU")
2177"IX",1130580001.101,1130580001.101,"MU",11.1,0)
2178^.114IA^1^1
2179"IX",1130580001.101,1130580001.101,"MU",11.1,1,0)
21801^F^1130580001.101^.3^30^1^F
2181"MBREQ")
21820
2183"PGL",1130580001.101,0,2,1)
2184NUMERATOR PATIENT LIST^P810.5'^PXRMXP(810.5,^0;2^Q
2185"PGL",1130580001.101,0,3,2)
2186DENOMINATOR PATIENT LIST^P810.5'^PXRMXP(810.5,^0;3^Q
2187"PGL",1130580001.101,7,2,1.1)
2188ALTERNATIVE NUMERATOR LIST^P1130580001.301'^C0Q(301,^7;2^Q
2189"PGL",1130580001.101,7,3,2.1)
2190ALTERNATIVE DENOMINATOR LIST^P1130580001.301'^C0Q(301,^7;3^Q
2191"PGL",1130580001.101,7,4,1.5)
2192NEGATIVE NUMERATOR LIST^P810.5'^PXRMXP(810.5,^7;4^Q
2193"PGL",1130580001.101,7,5,1.51)
2194ALTERNATE NEGATIVE NUM LIST^P1130580001.301'^C0Q(301,^7;5^Q
2195"PGL",1130580001.101,7,7,1.2)
2196NUMERATOR RULE SET^*P810.4'^PXRM(810.4,^7;7^S DIC("S")="I $P(^(0),U,3)=3" D ^DIC K DIC S DIC=$G(DIE),X=+Y K:Y<0 X
2197"PGL",1130580001.101,7,8,2.2)
2198DENOMINATOR RULE SET^*P810.4'^PXRM(810.4,^7;8^S DIC("S")="I $P(^(0),U,3)=3" D ^DIC K DIC S DIC=$G(DIE),X=+Y K:Y<0 X
2199"PGL",1130580001.101,7,9,2.5)
2200EXTRACT DEFINITION^P810.2'^PXRM(810.2,^7;9^Q
2201"PKG",215,-1)
22021^1
2203"PKG",215,0)
2204QUALITY MEASURES^C0Q^Tracks and Prints Quality Measures
2205"PKG",215,20,0)
2206^9.402P^^
2207"PKG",215,22,0)
2208^9.49I^1^1
2209"PKG",215,22,1,0)
22101.0^3120731^3120802^8
2211"PKG",215,22,1,"PAH",1,0)
22123^3120803
2213"PKG",215,22,1,"PAH",1,1,0)
2214^^5^5^3120803
2215"PKG",215,22,1,"PAH",1,1,1,0)
2216Created by Sam Habiel on July 13th 2012 for distribution with WorldVistA
2217"PKG",215,22,1,"PAH",1,1,2,0)
22182.0.
2219"PKG",215,22,1,"PAH",1,1,3,0)
2220
2221"PKG",215,22,1,"PAH",1,1,4,0)
2222Contains updated C0Q QUALITY MEASURES file containing the appropriate
2223"PKG",215,22,1,"PAH",1,1,5,0)
2224rule sets to use after each measure.
2225"QUES","XPF1",0)
2226Y
2227"QUES","XPF1","??")
2228^D REP^XPDH
2229"QUES","XPF1","A")
2230Shall I write over your |FLAG| File
2231"QUES","XPF1","B")
2232YES
2233"QUES","XPF1","M")
2234D XPF1^XPDIQ
2235"QUES","XPF2",0)
2236Y
2237"QUES","XPF2","??")
2238^D DTA^XPDH
2239"QUES","XPF2","A")
2240Want my data |FLAG| yours
2241"QUES","XPF2","B")
2242YES
2243"QUES","XPF2","M")
2244D XPF2^XPDIQ
2245"QUES","XPI1",0)
2246YO
2247"QUES","XPI1","??")
2248^D INHIBIT^XPDH
2249"QUES","XPI1","A")
2250Want KIDS to INHIBIT LOGONs during the install
2251"QUES","XPI1","B")
2252NO
2253"QUES","XPI1","M")
2254D XPI1^XPDIQ
2255"QUES","XPM1",0)
2256PO^VA(200,:EM
2257"QUES","XPM1","??")
2258^D MG^XPDH
2259"QUES","XPM1","A")
2260Enter the Coordinator for Mail Group '|FLAG|'
2261"QUES","XPM1","B")
2262
2263"QUES","XPM1","M")
2264D XPM1^XPDIQ
2265"QUES","XPO1",0)
2266Y
2267"QUES","XPO1","??")
2268^D MENU^XPDH
2269"QUES","XPO1","A")
2270Want KIDS to Rebuild Menu Trees Upon Completion of Install
2271"QUES","XPO1","B")
2272NO
2273"QUES","XPO1","M")
2274D XPO1^XPDIQ
2275"QUES","XPZ1",0)
2276Y
2277"QUES","XPZ1","??")
2278^D OPT^XPDH
2279"QUES","XPZ1","A")
2280Want to DISABLE Scheduled Options, Menu Options, and Protocols
2281"QUES","XPZ1","B")
2282NO
2283"QUES","XPZ1","M")
2284D XPZ1^XPDIQ
2285"QUES","XPZ2",0)
2286Y
2287"QUES","XPZ2","??")
2288^D RTN^XPDH
2289"QUES","XPZ2","A")
2290Want to MOVE routines to other CPUs
2291"QUES","XPZ2","B")
2292NO
2293"QUES","XPZ2","M")
2294D XPZ2^XPDIQ
2295"SEC","^DD",1130580001.101,1130580001.101,3.1,9)
2296
2297"SEC","^DIC",1130580001.101,1130580001.101,0,"AUDIT")
2298@
2299"SEC","^DIC",1130580001.101,1130580001.101,0,"DD")
2300@
2301"SEC","^DIC",1130580001.101,1130580001.101,0,"DEL")
2302@
2303"SEC","^DIC",1130580001.101,1130580001.101,0,"LAYGO")
2304@
2305"SEC","^DIC",1130580001.101,1130580001.101,0,"RD")
2306@
2307"SEC","^DIC",1130580001.101,1130580001.101,0,"WR")
2308@
2309"VER")
23108.0^22.0
2311"^DD",1130580001.101,1130580001.101,0)
2312FIELD^^.3^18
2313"^DD",1130580001.101,1130580001.101,0,"DDA")
2314N
2315"^DD",1130580001.101,1130580001.101,0,"DT")
23163111201
2317"^DD",1130580001.101,1130580001.101,0,"ID",.7)
2318W:$D(^(5)) " ",$P(^(5),U,1)
2319"^DD",1130580001.101,1130580001.101,0,"IX","B",1130580001.101,.01)
2320
2321"^DD",1130580001.101,1130580001.101,0,"NM","C0Q QUALITY MEASURE")
2322
2323"^DD",1130580001.101,1130580001.101,0,"PT",1130580001.2011,.01)
2324
2325"^DD",1130580001.101,1130580001.101,0,"VRPK")
2326QUALITY MEASURES
2327"^DD",1130580001.101,1130580001.101,.01,0)
2328NAME^RF^^0;1^K:$L(X)>30!($L(X)<1)!'(X'?1P.E) X
2329"^DD",1130580001.101,1130580001.101,.01,.1)
2330MEASURE NAME
2331"^DD",1130580001.101,1130580001.101,.01,1,0)
2332^.1
2333"^DD",1130580001.101,1130580001.101,.01,1,1,0)
23341130580001.101^B
2335"^DD",1130580001.101,1130580001.101,.01,1,1,1)
2336S ^C0Q(101,"B",$E(X,1,30),DA)=""
2337"^DD",1130580001.101,1130580001.101,.01,1,1,2)
2338K ^C0Q(101,"B",$E(X,1,30),DA)
2339"^DD",1130580001.101,1130580001.101,.01,3)
2340Answer must be 1-30 characters in length
2341"^DD",1130580001.101,1130580001.101,.01,"DT")
23423101012
2343"^DD",1130580001.101,1130580001.101,.3,0)
2344MU YEAR KEY^F^^7;6^K:$L(X)>30!($L(X)<1) X
2345"^DD",1130580001.101,1130580001.101,.3,.1)
2346MEANINGFUL USE YEAR KEY
2347"^DD",1130580001.101,1130580001.101,.3,3)
2348Answer must be 1-30 characters in length.
2349"^DD",1130580001.101,1130580001.101,.3,"DT")
23503111201
2351"^DD",1130580001.101,1130580001.101,.5,0)
2352TITLE^F^^1;1^K:$L(X)>240!($L(X)<3) X
2353"^DD",1130580001.101,1130580001.101,.5,.1)
2354MEASURE TITLE
2355"^DD",1130580001.101,1130580001.101,.5,3)
2356Answer must be 3-240 characters in length
2357"^DD",1130580001.101,1130580001.101,.5,"DT")
23583110430
2359"^DD",1130580001.101,1130580001.101,.61,0)
2360VERY LONG DESCRIPTION^1130580001.111^^6;0
2361"^DD",1130580001.101,1130580001.101,.7,0)
2362DISPLAY NAME^F^^5;1^K:$L(X)>240!($L(X)<3) X
2363"^DD",1130580001.101,1130580001.101,.7,.1)
2364QRDA DISPLAY NAME
2365"^DD",1130580001.101,1130580001.101,.7,3)
2366Answer must be 3-240 characters in length
2367"^DD",1130580001.101,1130580001.101,.7,"DT")
23683101012
2369"^DD",1130580001.101,1130580001.101,.8,0)
2370REPORTING NAME^F^^7;1^K:$L(X)>30!($L(X)<3) X
2371"^DD",1130580001.101,1130580001.101,.8,.1)
2372REPORTING MEASURE NAME
2373"^DD",1130580001.101,1130580001.101,.8,3)
2374Answer must be 3-30 characters in length
2375"^DD",1130580001.101,1130580001.101,.8,"DT")
23763110615
2377"^DD",1130580001.101,1130580001.101,1,0)
2378NUMERATOR PATIENT LIST^P810.5'^PXRMXP(810.5,^0;2^Q
2379"^DD",1130580001.101,1130580001.101,1,.1)
2380MEASURE NUMERATOR PATIENT LIST
2381"^DD",1130580001.101,1130580001.101,1,"DT")
23823101012
2383"^DD",1130580001.101,1130580001.101,1.1,0)
2384ALTERNATIVE NUMERATOR LIST^P1130580001.301'^C0Q(301,^7;2^Q
2385"^DD",1130580001.101,1130580001.101,1.1,"DT")
23863110805
2387"^DD",1130580001.101,1130580001.101,1.2,0)
2388NUMERATOR RULE SET^*P810.4'^PXRM(810.4,^7;7^S DIC("S")="I $P(^(0),U,3)=3" D ^DIC K DIC S DIC=$G(DIE),X=+Y K:Y<0 X
2389"^DD",1130580001.101,1130580001.101,1.2,3)
2390Enter the reminder rule set to use for this measure.
2391"^DD",1130580001.101,1130580001.101,1.2,12)
2392If the type of the reminder list rule is a Rule Set.
2393"^DD",1130580001.101,1130580001.101,1.2,12.1)
2394S DIC("S")="I $P(^(0),U,3)=3"
2395"^DD",1130580001.101,1130580001.101,1.2,21,0)
2396^^5^5^3120716^
2397"^DD",1130580001.101,1130580001.101,1.2,21,1,0)
2398This is the numerator reminder rule set to use for the quality measure.
2399"^DD",1130580001.101,1130580001.101,1.2,21,2,0)
2400
2401"^DD",1130580001.101,1130580001.101,1.2,21,3,0)
2402The rule set is used to generate a patient list, which this package
2403"^DD",1130580001.101,1130580001.101,1.2,21,4,0)
2404referneces. The contents of the patient list will produce the count for
2405"^DD",1130580001.101,1130580001.101,1.2,21,5,0)
2406the measure. This count is for the numerator.
2407"^DD",1130580001.101,1130580001.101,1.2,"DT")
24083120716
2409"^DD",1130580001.101,1130580001.101,1.5,0)
2410NEGATIVE NUMERATOR LIST^P810.5'^PXRMXP(810.5,^7;4^Q
2411"^DD",1130580001.101,1130580001.101,1.5,.1)
2412LIST OF PATIENTS THAT DO NOT MEET THE REQUIREMENTS
2413"^DD",1130580001.101,1130580001.101,1.5,"DT")
24143110809
2415"^DD",1130580001.101,1130580001.101,1.51,0)
2416ALTERNATE NEGATIVE NUM LIST^P1130580001.301'^C0Q(301,^7;5^Q
2417"^DD",1130580001.101,1130580001.101,1.51,.1)
2418NEGATIVE NUMERATOR LIST IN C0Q PATIENT LIST FILE
2419"^DD",1130580001.101,1130580001.101,1.51,"DT")
24203110809
2421"^DD",1130580001.101,1130580001.101,2,0)
2422DENOMINATOR PATIENT LIST^P810.5'^PXRMXP(810.5,^0;3^Q
2423"^DD",1130580001.101,1130580001.101,2,.1)
2424MEASURE DENOMINATOR PATIENT LIST
2425"^DD",1130580001.101,1130580001.101,2,"DT")
24263101012
2427"^DD",1130580001.101,1130580001.101,2.1,0)
2428ALTERNATIVE DENOMINATOR LIST^P1130580001.301'^C0Q(301,^7;3^Q
2429"^DD",1130580001.101,1130580001.101,2.1,"DT")
24303110805
2431"^DD",1130580001.101,1130580001.101,2.2,0)
2432DENOMINATOR RULE SET^*P810.4'^PXRM(810.4,^7;8^S DIC("S")="I $P(^(0),U,3)=3" D ^DIC K DIC S DIC=$G(DIE),X=+Y K:Y<0 X
2433"^DD",1130580001.101,1130580001.101,2.2,3)
2434Enter the reminder rule set to use for this measure.
2435"^DD",1130580001.101,1130580001.101,2.2,12)
2436If the type of the reminder list rule is a Rule Set.
2437"^DD",1130580001.101,1130580001.101,2.2,12.1)
2438S DIC("S")="I $P(^(0),U,3)=3"
2439"^DD",1130580001.101,1130580001.101,2.2,21,0)
2440^^5^5^3120716^
2441"^DD",1130580001.101,1130580001.101,2.2,21,1,0)
2442This is the denominator reminder rule set to use for the quality measure.
2443"^DD",1130580001.101,1130580001.101,2.2,21,2,0)
2444
2445"^DD",1130580001.101,1130580001.101,2.2,21,3,0)
2446The rule set is used to generate a patient list, which this package
2447"^DD",1130580001.101,1130580001.101,2.2,21,4,0)
2448referneces. The contents of the patient list will produce the count for
2449"^DD",1130580001.101,1130580001.101,2.2,21,5,0)
2450the measure. This count is for the denominator.
2451"^DD",1130580001.101,1130580001.101,2.2,"DT")
24523120716
2453"^DD",1130580001.101,1130580001.101,2.5,0)
2454EXTRACT DEFINITION^P810.2'^PXRM(810.2,^7;9^Q
2455"^DD",1130580001.101,1130580001.101,2.5,3)
2456Select a Reminder Extract Definition for this measure
2457"^DD",1130580001.101,1130580001.101,2.5,21,0)
2458^^4^4^3120726^
2459"^DD",1130580001.101,1130580001.101,2.5,21,1,0)
2460If this measure depends upon a reminder extract definition, you can add
2461"^DD",1130580001.101,1130580001.101,2.5,21,2,0)
2462this extract definition here. This will alter how the Quality Measures
2463"^DD",1130580001.101,1130580001.101,2.5,21,3,0)
2464package computes the measure to use the extract in addition and prior to
2465"^DD",1130580001.101,1130580001.101,2.5,21,4,0)
2466the rule sets.
2467"^DD",1130580001.101,1130580001.101,2.5,"DT")
24683120726
2469"^DD",1130580001.101,1130580001.101,3,0)
2470QRDA TEMPLATE ROOT^F^^0;4^K:$L(X)>120!($L(X)<3) X
2471"^DD",1130580001.101,1130580001.101,3,.1)
2472MEASURE TEMPLATE ROOT FOR QRDA DOCUMENT
2473"^DD",1130580001.101,1130580001.101,3,3)
2474Answer must be 3-120 characters in length
2475"^DD",1130580001.101,1130580001.101,3,"DT")
24763101012
2477"^DD",1130580001.101,1130580001.101,3.1,0)
2478QRDA MEASURE SYSTEM OID^CJ^^ ; ^S X="2.16.840.1.113883.3.249.12"
2479"^DD",1130580001.101,1130580001.101,3.1,.1)
2480QRDA SYSTEM OID (FIXED)
2481"^DD",1130580001.101,1130580001.101,3.1,9.01)
2482
2483"^DD",1130580001.101,1130580001.101,3.1,9.1)
2484S X="2.16.840.1.113883.3.249.12"
2485"^DD",1130580001.101,1130580001.101,3.1,"DT")
24863101012
2487"^DD",1130580001.101,1130580001.101,3.2,0)
2488QRDA CODE^F^^4;1^K:$L(X)>80!($L(X)<1) X
2489"^DD",1130580001.101,1130580001.101,3.2,.1)
2490QRDA MEASURE CODE
2491"^DD",1130580001.101,1130580001.101,3.2,3)
2492Answer must be 1-80 characters in length
2493"^DD",1130580001.101,1130580001.101,3.2,"DT")
24943101012
2495"^DD",1130580001.101,1130580001.111,0)
2496VERY LONG DESCRIPTION SUB-FIELD^^.01^1
2497"^DD",1130580001.101,1130580001.111,0,"DT")
24983101013
2499"^DD",1130580001.101,1130580001.111,0,"NM","VERY LONG DESCRIPTION")
2500
2501"^DD",1130580001.101,1130580001.111,0,"UP")
25021130580001.101
2503"^DD",1130580001.101,1130580001.111,.01,0)
2504VERY LONG DESCRIPTION^Wx^^0;1
2505"^DD",1130580001.101,1130580001.111,.01,.1)
2506LONGER DESCRIPTION - IF IT DOESN'T FIT IN .6
2507"^DD",1130580001.101,1130580001.111,.01,3)
2508LONGER DESCRIPTION - INSTEAD OF LONG DESCRIPTION
2509"^DD",1130580001.101,1130580001.111,.01,"DT")
25103101013
2511"^DIC",1130580001.101,1130580001.101,0)
2512C0Q QUALITY MEASURE^1130580001.101
2513"^DIC",1130580001.101,1130580001.101,0,"GL")
2514^C0Q(101,
2515"^DIC",1130580001.101,"B","C0Q QUALITY MEASURE",1130580001.101)
2516
2517**END**
2518**END**
Note: See TracBrowser for help on using the repository browser.